

A

- Abel, M. S., *see* Garrett, K. M., 652
 Aduhya, T., *see* Quik, M., 90
 Afar, R., *see* Quik, M., 90
 Ahluwalia, G. S., *see* Masood, R., 590
 Andries, M. J., Lucier, G. W., Goldstein, J., and Thompson, C. L. Involvement of cytochrome P-450c in α -naphthoflavone metabolism by rat liver microsomes, 990
 Arbonés, L., Picatoste, F., and Garcia, A. Histamine stimulates glycogen breakdown and increases $^{45}\text{Ca}^{2+}$ permeability in rat astrocytes in primary culture, 921
 Archer, S., *see* Bidlack, J. M., 50
 Armah, B. I., *see* Wang, G., 17, 144
 Arnold, S. T., *see* Politi, P. M., 790
 Aronin, N., *see* Madras, B. K., 833
 Ashmun, R., *see* Fridland, A., 665
 Ashton, R. A., *see* Garrett, K. M., 652
 Ayer, D. E., *see* Im, W. B., 429
 Aylwin, M., *see* White, M. M., 720

B

- Báez, A., Riou, J. F., Le Pecq, J. B., and Riou, G. Interaction of DNA intercalator 3-nitrobenzothiazolo (3,2- α)quinolinium with DNA topoisomerases: A possible-mechanism for its biological activity, 377
 Baidur, N., *see* Madras, B. K., 833
 Bakthavachalam, V., *see* Madras, B. K., 833
 Balzarini, J., Bernaerts, R., Verbruggen, A., and De Clercq, E. Role of the incorporation of (*E*)-5-(2-iodovinyl)-2'-deoxyuridine and its carbocyclic analogue into DNA of herpes simplex virus type 1-infected cells in the antiviral effects of these compounds, 402
 Balzarini, J., De Clercq, E., Baumgartner, H., Bodenteich, M., and Griengl, H. Carbocyclic 5-iodo-2'-deoxyuridine (C-IDU) and carbocyclic (*E*)-5-(2-bromovinyl)-2'-deoxyuridine (C-BVDU) as unique examples of chiral molecules where the two enantiomeric forms are biologically active: Interaction of the (+)- and (-)-enantiomers of C-IDU and C-BVDU with the thymidine kinase of herpes simplex virus type I, 395
 Balzarini, J., *see* Hao, Z., 157
 Banet, D. E., *see* Sherratt, A. J., 198
 Barber, R., *see* Prashad, N., 937
 Barbour, K. W., Berger, S. H., and Berger, F. G. Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase, 515
 Baron, J., *see* Voigt, J. M., 182
 Barrington, W. W., *see* Ramkumar, V., 149
 Bast, A., *see* Haenen, G. R. M. M., 412
 Baudry, M., *see* Massicotte, G., 278
 Baumgartner, H., *see* Balzarini, J., 395
 Beauwens, R., *see* Van Sande, J., 583
 Beer, B., *see* Garrett, K. M., 652
 Bell, J. D., Biltonen, R. L., and Brunton, L. L. Non-steady state kinetic analysis of the regulation of adenylate cyclase by GTP-binding proteins, 535
 Benz, C. C., Keniry, M. A., Ford, J. M., Townsend, A. J., Cox, F. W., Palayoor, S., Matlin, S. A., Hait, W. N., and Cowan, K. H. Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers, 840
 Berger, F. G., *see* Barbour, K. W., 515
 Berger, S. H., *see* Barbour, K. W., 515
 Berhane, K., and Mannervik, B. Inactivation of the genotoxic aldehyde acrolein by human glutathione transferases of classes Alpha, Mu, and Pi, 251

- Berkovich, A., McPhie, P., Campagnone, M., Guidotti, A., and Hensley, P. A natural processing product of rat diazepam binding inhibitor, triakontatetrapeptide (diazepam binding inhibitor 17-50) contains an α -helix, which allows discrimination between benzodiazepine binding site subtypes, 164
 Bernaerts, R., *see* Balzarini, J., 402
 Bernaerts, R., *see* De Clercq, E., 658
 Biaggioni, I., *see* Paul, S., 870
 Bidlack, J. M., Frey, D. K., Kaplan, R. A., Seyed-Mozaffari, A., and Archer, S. Affinity labeling of μ opioid receptors by sulfhydryl alkylating derivatives of morphine and morphinone, 50
 Biesterfeldt, J. P., *see* Monahan, J. B., 780
 Biltonen, R. L., *see* Bell, J. D., 535
 Binaschi, M., *see* De Isabella, P., 11
 Blakeman, D. P., *see* Im, W. B., 429
 Blakley, R. L., Harwood, F. C., and Huff, K. D. Cytostatic effects of 2',3'-dideoxyribonucleosides on transformed human hemopoietic cell lines, 328
 Blume, A. J., *see* Garrett, K. M., 652
 Bockaert, J., Sebben, M., and Dumuis, A. Pharmacological characterization of 5-hydroxytryptamine, (5-HT₄) receptors positively coupled to adenylate cyclase in adult guinea pig hippocampal membranes: Effect of substituted benzamide derivatives, 408
 Bodenteich, M., *see* Balzarini, J., 395
 Boeynaems, J. M., *see* Demolle, D., 827
 Bogucki, B. D., *see* Rettie, A. E., 643
 Bohmaker, K., *see* Meller, E., 231
 Border, S., *see* Masood, R., 590
 Borislow, S., *see* He, H.-T., 614
 Bös, M., *see* Cesura, A. M., 358
 Bouterin-Falson, O., *see* Demolle, D., 827
 Bowyer, J. F., *see* Houchi, H., 104
 Brakeman, J. C., *see* Van Sande, J., 583
 Brann, M. R., *see* Stormann, T. M., 1
 Brennan, S. O., *see* Kragh-Hansen, U., 238
 Brodersen, R., Jørgensen, N. A., Vorum, H., and Krukow, N. Valproate and palmitate binding to human serum albumin: An hypothesis on obesity, 704
 Bruno, V., *see* Nicoletti, F., 689
 Brunton, L. L., *see* Bell, J. D., 535
 Brush, K., *see* Chu, A., 735
 Buller, A. L., and White, M. M. Functional acetylcholine receptors expressed in *Xenopus* oocytes after injection of *Torpedo* β , γ , and δ subunit RNAs are a consequence of endogenous oocyte gene expression, 423
 Burch, R. M., *see* Mahan, L. C., 785
 Bureau, M., and Olsen, R. W. Multiple distinct subunits of the γ -aminobutyric acid-A receptor protein show different ligand-binding affinities, 497
 Burke, J. P., *see* Voigt, J. M., 182
 Burnett, D. M., Daniell, L. C., and Zahniser, N. R. Decreased efficacy of inositol 1,4,5-trisphosphate to elicit calcium mobilization from cerebrocortical microsomes of aged rats, 566
 Butcher, R. W., *see* Prashad, N., 937

C

- Campagnone, M., *see* Berkovich, A., 164
 Canfield, D. R., *see* Madras, B. K., 833
 Canonico, P. L., *see* Nicoletti, F., 689
 Capranico, G., *see* De Isabella, P., 11
 Cashman, J. R., and Williams, D. E. Enantioselective *S*-oxygenation of 2-aryl-1,3-dithiolanes by rabbit lung enzyme preparations, 333

- Cashman, J. R., Olsen, L. D., Lambert, C. E., and Presas, M. J. Enantioselective *S*-oxygenation of *para*-methoxyphenyl-1,3-dithiolane by various tissue preparations: Effect of estradiol, 319
- Cavallaro, S., *see* Nicoletti, F., 689
- Cesura, A. M., Bös, M., Galva, M. D., Imhof, R., and Da Prada, M. Characterization of the binding of [³H]Ro 41-1049 to the active site of human monoamine oxidase-A, 358
- Chang, R. S. L., and Lotti, V. J. Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands, 347
- Chen, S., *see* Liu, X.-F., 911
- Cheung, A. H., Dixon, R. A. F., Hill, W. S., Sigal, I. S., and Strader, C. D. Separation of the structural requirements for agonist-promoted activation and sequestration of the β -adrenergic receptor, 775
- Cheung, A. H., *see* Huang, R.-R. C., 304
- Choi, O. H., Padgett, W. L., Nishizawa, Y., Gusovsky, F. Yasumoto, T., and Daly, J. W. Maitotoxin: Effects of calcium channels, phosphoinositide breakdown, and arachidonate release in pheochromocytoma PC12 cells, 222
- Chu, A., Diaz-Munoz, M., Hawkes, M. J., Brush, K., and Hamilton, S. L. Ryanodine as a probe for the functional state of the skeletal muscle sarcoplasmic reticulum calcium release channel, 735
- Cieslinski, L. B., *see* Torphy, T. J., 206
- Clements, D. J., *see* Cole, S. P. C., 192
- Cler, J. A., *see* Rao, T. S., 978
- Cole, S. P. C., Downes, H. F., Mirski, S. E. L., and Clements, D. J. Alterations in glutathione and glutathione-related enzymes in a multidrug-resistant small cell lung cancer cell line, 192
- Compton, R. P., *see* Monahan, J. B., 780
- Connelly, M. C., *see* Fridland, A., 665
- Conner, D. A., and Mansour, T. E. Serotonin receptor-mediated activation of adenylate cyclase in the neuroblastoma NCB.20: A novel 5-hydroxytryptamine receptor, 742
- Connor, H. D., Lacagnin, L. B., Knecht, K. T., Thurman, R. G., and Mason, R. P. Reaction of glutathione with a free radical metabolite of carbon tetrachloride, 443
- Coon, M. J., *see* Ding, X., 489
- Cooney, D. A., *see* Hao, Z., 157
- Cooney, D. A., *see* Masood, R., 590
- Copani, A., *see* Nicoletti, F., 689
- Cordi, A. A., *see* Monahan, J. B., 780
- Costa, T., Lang, J., Gless, C., and Herz, A. Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: Specific regulation by antagonists and sodium ions, 383
- Courtney, K. R. Sodium channel blockers: The size/solubility hypothesis revisited, 855
- Covey, D. F., *see* Holland, K. D., 98
- Cowan, K. H., *see* Benz, C. C., 840
- Cowan, K. H., *see* Fairchild, C. R., 801
- Cox, F. W., *see* Benz, C. C., 840
- Coy, D. H., *see* Rorstad, O. P., 971
- Cragoe, E. J., Jr., *see* Demolle, D., 827
- Crippen, G. M., *see* Ghose, A. K., 725
- D**
- Daloze, D., *see* Van Sande, J., 583
- Daly, J. W., *see* Choi, O. H., 222
- Daniell, L. C., *see* Burnett, D. M., 566
- Da Prada, M., *see* Cesura, A. M., 358
- Dave, J. R., Tabakoff, B., and Hoffman, P. L. Ethanol withdrawal seizures produce increased *c-fos* mRNA in mouse brain, 367
- Davis, J. P., *see* Im, W. B., 429
- Davis, R. L., *see* Henkel-Tigges, 7
- De Castiglione, R., *see* Lazarus, L. H., 886
- De Clercq, E., Bernaerts, R., Merta, A., and Rosenwirth, B. Mechanism of action of 5-(2-chloroethyl)-2'-deoxyuridine, a selective inhibitor of herpes simplex virus replication, 658
- De Clercq, E., *see* Balzarini, J., 395, 402
- Dehaven, R. N., *see* Huang, R.-R. C., 304
- De Isabella, P., Capranico, G., Binaschi, M., Tinelli, S., and Zunino, F. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 Leukemia cells, 11
- Demolle, D., Lecomte, M., Bouterin-Falson, O., Cragoe, E. J., Jr., Nairn, A. C., and Boeynaems, J. M. Amiloride analogs induce the phosphorylation of elongation factor-2 in vascular endothelial cells, 827
- Deneubourg, F., *see* Van Sande, J., 583
- Den Kelder, G. M. D.-O., *see* Koymans, L., 452
- De Rooij, B. M., *see* Haenen, G. R. M. M., 412
- Desarmenien, M., *see* Hamann, M., 578
- Dhar, A., Paul, A. K. and Shukla, S. D. Platelet-activating factor stimulation of tyrosine kinase and its relationship to phospholipase C in rabbit platelets: Studies with genistein and monoclonal antibody to phosphotyrosine, 519
- Diaz-Munoz, M., *see* Chu, A., 735
- Diehl, R. E., *see* Huang, R.-R. C., 304
- Difiglia, M., *see* Madras, B. K., 833
- Ding, X., and Coon, M. J. Immunochemical characterization of multiple forms of cytochrome P-450 in rabbit nasal microsomes and evidence for tissue-specific expression of P-450s NMa and NMb, 489
- Dirksen, R. T., *see* Enyeart, J. J., 752
- Dixon, R. A. F., *see* Cheung, A. H., 775
- Dixon, R. A. F., *see* Huang, R.-R. C., 304
- Doehmer, J., *see* Dogra, S., 608
- Dogra, S., Doehmer, J., Glatt, H., Siegert, P., Friedberg, T., Seidel, A., and Oesch, F. Stable expression of rat cytochrome P-450IA1 cDNA in V79 Chinese hamster cells and their use in mutagenicity testing, 608
- Downes, H. F., *see* Cole, S. P. C., 192
- Driscoll, J. S., *see* Masood, R., 590
- Dugas, M., *see* Wang, G., 17, 144
- Duman, R. S., *see* Garrett, K. M., 652
- Dumont, J. E., *see* Van Sande, J., 583
- Dumuis, A., *see* Bockaert, J., 408
- Durie, E. L., *see* Pessah, I. N., 503
- E**
- El-Fakahany, E. E., *see* Forray, C., 893
- El-Fakahany, E. E., *see* Surichamorn, W., 860
- Emmett, M. R., *see* Rao, T. S., 978
- Enyeart, J. J., Dirksen, R. T., Sharma, V. K., Williford, D. J., and Sheu, S.-S. Antipsychotic pimozide is a potent Ca²⁺ channel blocker in heart, 752
- Enz, A., Goldstein, M., and Meller, E. Dopamine agonist-induced elevation of striatal acetylcholine: Relationship between receptor occupancy and response in normal and denervated rat striatum, 560
- Evans, W. E., and Relling, M. V. *Xba*I 16 - and 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: Report of a family study, 639
- Eyer, P., *see* Maples, K. R., 311
- F**
- Fahien, C. M., *see* Fahien, L. A., 943
- Fahien, L. A., Teller, J. K., Macdonald, M. J., and Fahien, C. M. Regulation of glutamate dehydrogenase by Mg²⁺ and magnification of leucine activation by Mg²⁺, 943
- Fairchild, C. R., Moscow, J. A., O'Brien, E. E., and Cowan, K. H. Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase- π , 801
- Farb, D. H., *see* Roca, D. J., 37, 710
- Farb, D. H., *see* Wu, F.-S., 597
- Farber, J. L., *see* Sakaida, I., 435
- Farquhar, D., *see* Hao, Z., 157

- Farrant, M., *see* Roca, D. J., 37
Felsted, R. L., *see* Politi, P. M., 790
Feltz, P., *see* Hamann, M., 578
Feoktistov, I., *see* Paul, S., 870
Ferrendelli, J. A., *see* Holland, K. D., 98
Ford, J. M., *see* Benz, C. C., 840
Forray, C., and El-Fakahany, E. E. On the involvement of multiple muscarinic receptor subtypes in the activation of phosphoinositide metabolism in rat cerebral cortex, 893
Forray, C., *see* Surichamorn, W., 860
Fournier, A., *see* Rorstad, O. P., 971
Fox, I. H., *see* Zolnierowicz, S., 554
Freidman, E., *see* Wang, H.-Y., 75
Frey, D. K., *see* Bidlack, J. M., 50
Fridland, A., Connelly, M. C., and Ashmun, R. relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3'-azido-3'-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM), 665
Fridland, A., *see* Masood, R., 590
Friedberg, T., *see* Dogra, S., 608
Friedman, L., *see* Roca, D. J., 710
Froimowitz, M., *see* Leli, U., 286
Fujimori, S., *see* Garrett, K. M., 652
- G**
- Gago, F., and Richards, W. G. Netropsin binding to poly[d(IC)] poly[IC] and poly[d(GC)] poly[d(GC)]: A computer simulation, 341
Galliano, M., *see* Kragh-Hansen, U., 238
Galva, M. D., *see* Cesura, A. M., 358
Garcia, A., *see* Arbonés, L., 921
Garrett, K. M., Saito, N., Duman, R. S., Abel, M. S., Ashton, R. A., Fujimori, S., Beer, B., Tallman, J. F., Vitek, P., and Blume A. J. differential expression of γ -aminobutyric acid_A receptor subunits, 652
Gdula, D. C., *see* Stormann, T. M., 1
Geertsen, S., *see* Quik, M., 90
Gelboin, H. V., *see* Riddick, D. S., 130
Gerhardt, M. A., *see* Michel, M. C., 65
Ghose, A. K., and Crippen, G. M. Modeling the benzodiazepine receptor binding site by the general three-dimensional structure-directed quantitative structure-activity relationship method REMOTED-ISC, 725
Gibbs, T. T., *see* Roca, D. J., 710
Gibbs, T. T., *see* Wu, F.-S., 597
Gierschik, P., *see* Reithmann, C., 631
Gies, J. P., *see* Haddad, E. B., 682
Glatt, H., *see* Dogra, S., 608
Gless, C., *see* Costa, T., 383
Gnegy, M. E., *see* Mangels, L. A., 820
Goka, T. J., *see* Prashad, N., 937
Goldstein, G., *see* Quik, M., 90
Goldstein, J., *see* Andries, M. J., 990
Goldstein, M., *see* Enz, A., 560
Goldstein, M., *see* Meller, E., 231
Gonzalez, H., *see* Pan, S.-S., 966
Gorski, J., *see* Shull, J. D., 215
Graham, R. M., *see* Terman, B. I., 526
Grapengiesser, E., Gylfe, E., and Hellman, B. Sulfonylurea mimics the effect of glucose in inducing large amplitude oscillations of cytoplasmic Ca²⁺ in pancreatic β -cells, 461
Griengl, H., *see* Balzarini, J., 395
Grodski, S., *see* Terman, B. I., 526
Gross, R. A., Willey, J. W., Ryan-Jastrow, T. and Macdonald, R. L. Regulation by GTP and its stable thiol derivatives of calcium current components in rat nodose ganglion neurons, 546
Grudt, T. J., and Jahr, C. E. Quisqualate activates *N*-methyl-D-aspartate receptor channels in hippocampal neurons maintained in culture, 477
Guengerich, F. P., *see* Voigt, J. M., 182
Guglietta, A., *see* Lazarus, L. H., 886
Guidotti, A., *see* Berkovich, A., 164
Guillouzo, A., *see* Vandenberghe, Y., 372
Gumucio, J. J., *see* Traber, P. G., 810
Gusovsky, F., *see* Choi, O. H., 222
Guyda, H. J., Mathieu, L., Lai, W., Manchester, D., Wang, S.-L., Ogilvie, S., and Shiverick, K. T. Benzo(a)pyrene inhibits epidermal growth factor binding and receptor autophosphorylation in human placental cell cultures, 137
Gylfe, E., *see* Grapengiesser, E., 461
- H**
- Haddad, E. B., Landry, Y., and Gies, J. P. Sialic acid residues as catalysts for M₂-muscarinic agonist-receptor interactions, 682
Haenen, G. R. M. M., De Rooij, B. M., Vermeulen, N. P. E., and Bast, A. Mechanism of the reaction of ebselen with endogenous thiols: Dihydrolipoate is a better cofactor than glutathione in the peroxidase activity of ebselen, 412
Hait, W. N., *see* Benz, C. C., 840
Halpern, J. L., and Moss, J. Immunological characterization of of guanine nucleotide-binding protein: Effects of a monoclonal antibody against the γ subunit of transducin on guanine nucleotide-binding protein-receptor interactions, 797
Hamann, M., Desarmenien, M., Vanderheyden, P., Pigué, P., and Feltz, P. Electrophysical study of *tert*-butylbicyclopentylphosphorothionate-induced block of spontaneous chloride channel, 578
Hamilton, S. L., *see* Chu, A., 735
Han, C., Wilson, K. M., and Minneman, K. P. α_1 -Adrenergic receptor subtypes and formation of inositol phosphates in dispersed hepatocytes and renal cells, 903
Hao, Z., Cooney, D. A., Farquhar, D., Perno, C. F., Zhang, K., Masood, R., Wilson, Y., Hartman, N. R., Balzarini, J., and Johns, D. G. Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxyuridine-5'-triphosphate, 157
Hao, Z., *see* Masood, R., 590
Hartman, N. R., *see* Hao, Z., 157
Harwood, F. C., *see* Blakely, R. L., 328
Haslam, R. J., *see* Maurice, D. H., 671
Hauser, G., *see* Leli, U., 286
Hawkes, M. J., *see* Chu, A., 735
Hayden, P. J., and Stevens, J. L. Cysteine conjugate toxicity, metabolism, and binding to macromolecules in isolated rat kidney mitochondria, 468
He, H.-T., Rens-Domiano, S., Martin, J.-M., Law, S., Borislow, S., Woolkalis, M., Manning, D., and Reisine, T. Solubilization of active somatostatin receptors from rat brain, 614
Hellman, B., *see* Grapengiesser, E., 461
Henkel-Tigges, J., and Davis, R. L. Rat homologs of the *Drosophila dunce* gene code for cyclic AMP phosphodiesterases sensitive to rolipram and RO 20-1724, 7
Hensley, P., *see* Berkovich, A., 164
Herz, A., *see* Costa, T., 383
Hess, H.-J., *see* Terman, B. I., 526
Hill, W. S., *see* Cheung, A. H., 775
Hiratsuka, A., *see* Ishizuka, T., 983
Hiratsuka, A., *see* Ogura, K., 848
Hoffman, P. L., *see* Dave, J. R., 372, 367 Vandenberghe, Y., Morel, F., Pemble, S., Tayl, units 1-2 and 7 in cultured rat hepatocytes
Holland, K. D., Naritoku, D. K., McKeon, A. C., Ferrendelli, J. A., and Covey, D. F. Convulsant and anticonvulsant cyclopentanones and cyclohexanones, 98
Hollister, A. S., *see* Paul, S., 870
Honerjäger, P., *see* Wang, G., 17, 144

- Hood, W. F., *see* Monahan, J. B., 780
 Hooper, W. D., *see* Reilly, P. E. B., 767
 Houchi, H., Masserano, J. M., Bowyer, J. F., and Weiner, N. Regulation of tyrosine hydroxylase activity in pheochromocytoma PC-12 cells by bradykinin, 104
 Huang, M., *see* Rorstad, O. P., 971
 Huang, R.-R. C., Dehaven, R. N., Cheung, A. H., Diehl, R. E., Dixon, R. A. F., and Strader, C. D. Identification of allosteric antagonists of receptor-guanine nucleotide-binding protein interactions, 304
 Huang, T.-J., and Maines, M. D. Bromobenzene-mediated alteration in activity and electrophoretic pattern of biliverdin reductase variants in rat kidney, 25
 Huff, K. D., *see* Blakely, R. L., 328
 Hunchak, K., *see* Mills, D. C. B., 271
 Hutchison, K., *see* Zolnierowicz, S., 554

I

- Im, W. B., Blakeman, D. P., Davis, J. P., and Ayer, D. E. Studies on the mechanism of interactions between anesthetic steroids and γ -aminobutyric acid_A receptors, 429
 Imhof, R., *see* Cesura, A. M., 358
 Insel, P. A., *see* Jasper, J. R., 44
 Insel, P. A., *see* Michel, M. C., 65
 Ishizuka, T., Komiya, I., Hiratsuka, A., and Watabe T. Novel type of ornithine-glutathione double conjugate excreted as a major metabolite into the bile of rats administered clebopride, 983
 Ivins, K. J., and Molinoff, P. B. Serotonin 5-Hydroxytryptamine₂ receptors coupled to phosphoinositide hydrolysis in a clonal cell line, 622
 Iwahashi, K., *see* Nakanishi, S., 482
 Iyanagi, T., *see* Liu, X.-F., 911
 Iyengar, S., *see* Rao, T. S., 978

J

- Jacobson, K. A., *see* Ramkumar, V., 149
 Jahr, C. E. *see* Grudt, T. J., 477
 Jakobs, K. H., *see* Reithmann, C., 631
 Jasper, J. R., Michel, M. C., and Insel, P. A. Amplification of cyclic AMP generation reveals agonistic effects of certain β -adrenergic antagonists, 44
 Javitt, D. C., and Zukin, S. R. Rat brain *N*-methyl-D-aspartate receptors require multiple molecules of agonist for activation, 603
 Jenkins, B. G., and Lauffer, R. B. Detection of site-specific binding and co-binding of ligands to human serum albumin using ¹⁹F NMR, 111
 Johns, D. G., *see* Hao, Z., 157
 Johns, D. G., *see* Masood, R., 590
 Johnson, K. M., *see* Sacca, A. I., 572
 Johnson, R. A., and Toews, M. L. Protein kinase C activators sensitize cyclic AMP accumulation by intact 1321N1 human astrocytoma cells, 296
 Jørgensen, N. A., *see* Brodersen, R., 704

K

- Kaplan, R. A., *see* Bidlack, J. M., 50
 Karl, D. W., *see* Mills, D. C. B., 271
 Kase, H., *see* Nakanishi, S., 482
 Kato, R., *see* Nakaki, T., 30
 Kawabata, T. T., *see* Voigt, J. M., 182
 Keniry, M. A., *see* Benz, C. C., 840
 Kessler, M., *see* Massicotte, G., 278
 Ketterer, B., *see* Vandenberghe, Y., 372
 Kirby, E. P., *see* Mills, D. C. B., 271
 Klopman, G., and Srivastava, S. Computer-automated structure evaluation of gastric antiulcer compounds: Study of cytoprotective and anti-secretory imidazo[1,2-a]pyridines and -pyrazines, 958

- Klotz, K.-N., *see* Wilken, A., 916
 Knecht, K. T., *see* Connor, H. D., 443
 Komiya, I., *see* Ishizuka, T., 983
 Koymans, L., Van Lenthe, J. H., Den Kelder, G. M. D.-O. and Vermeulen, N. P. E. Mechanisms of activation of phenacetin to reactive metabolites by cytochrome P-450: A theoretical study involving radical intermediates, 452
 Kozikowski, A. P., and Pan, Y.-P. Structural determinants of affinity for the phencyclidine binding site of the *N*-methyl-D-aspartate receptor complex: Discovery of a rigid phencyclidine analogue of high binding affinity, 352
 Kragh-Hansen, U., Brennan, S. O., Galliano, M., and Sugita, O. Binding of warfarin, salicylate, and diazepam to genetic variants of human serum albumin with known mutations, 238
 Krukow, N., *see* Brodersen, R., 704
 Kuroda, K., *see* Nakanishi, S., 482
 Kyle, M. E., *see* Sakaida, I., 435

L

- Lacagnin, L. B., *see* Connor, H. D., 443
 Lafontan, M., *see* Langin, D., 876
 Lai, W., *see* Guyda, H. J., 137
 Lambert, C. E., *see* Cashman, J. R., 319
 Landry, Y., *see* Haddad, E. B., 682
 Lang, J., *see* Costa, T., 383
 Langin, D., Paris, H., and Lafontan, M. Binding of [³H]Idazoxan and of its methoxy derivative [³H] RX821002 in human fat cells: [³H] Idazoxan but not [³H] RX821002 labels additional non- α_2 -adrenergic binding sites, 876
 Lanthorn, T. H., *see* Monahan, J. B., 780
 Lauffer, R. B., *see* Jenkins, B. G., 111
 Laurenza, A., Morris, D., and Seamon, K. B. Irreversible loss of [³H] forskolin binding sites in human platelets by :ga-haloacetyl analogs of forskolin, 69
 Law, S., *see* He, H.-T., 614
 Laychock, S. G. Fatty acids and cyclooxygenase and lipoxigenase pathway inhibitors modulate inositol phosphate formation in pancreatic islets, 928
 Lazarus, L. H., Wilson, W. E., Guglietta, A., and De Castiglione, R. Dermorphin interaction with rat brain opioid receptors: Involvement of hydrophobic sites in the binding domain, 886
 Lecomte, M., *see* Demolle, D., 827
 Lee, T. D., *see* Liu, X.-F., 911
 Legesse, K., *see* Liu, X.-F., 911
 Leli, U., Hauser, G., and Froimowitz, M. Requirements for the activation of protein kinase C: Comparison of the molecular geometries of phorbol and diacylglycerol, 286
 Lemaire, S., *see* Murphy, B. J., 173
 Le Pecq, J. B., *see* Báez, A., 377
 Li, S., *see* Liu-Chen, L.-Y., 243
 Lim, I., *see* Rettie, A. E., 643
 Liu, M.-L., *see* Liu, X.-F., 911
 Liu, X.-F., Liu, M.-L., Iyanagi, T., Legesse, K., Lee, T. D., and Chen, S. Inhibition of rat liver NAD(P)H: Quinone acceptor oxidoreductase (DT-diaphorase) by flavonoids isolated from the Chinese herb scutellariae radix (Huang Qin), 911
 Liu-Chen, L.-Y., Li, S., and Tallarida, R. J. Studies on kinetics of [³H] β -funaltrexamine binding to μ opioid receptor, 243
 Lotti, V. J., *see* Chang, R. S. L., 347
 Lucier, G. W., *see* Andries, M. J., 990
 Lynch, G., *see* Massicotte, G., 278

M

- Macdonald, M. J., *see* Fahien, L. A., 943
 Macdonald, R. L. *see* Gross, R. A., 546

- Madras, B. K., Canfield, D. R., Pfaelzer, C., Vittimberga, F. J., Jr., Difiglia, M., Aronin, N., Bakthavachalam, V., Baidur, N., and Neumeyer, J. L. Fluorescent and biotin probes for dopamine receptors: D₁ and D₂ receptor affinity and selectivity, 833
- Magnan, J., *see* Tiberi, M., 694
- Mahan, L. C., and Burch, R. M. Functional expression of B₂ bradykinin receptors from Balb/c cell mRNA in *Xenopus* oocytes, 785
- Maines, M. D., *see* Huang, T.-J., 25
- Manchester, D., *see* Guyda, H. J., 137
- Mangels, L. A., and Gnegy, M. E. Muscarinic receptor-mediated translocation of calmodulin in SK-N-SH human neuroblastoma cells, 820
- Mannervik, B., *see* Berhane, K., 251
- Manning, D., *see* He, H.-T., 614
- Mansour, T. E., *see* Conner, D. A., 742
- Maples, K. R., Eyer, P., and Mason, R. P. Aniline-, phenylhydroxylamine-, nitrosobenzene-, and nitrobenzene-induced hemoglobin thiol free radical formation *in vivo* and *in vitro*, 311
- Marks, G. S., *see* Riddick, D. S., 130
- Marquez, A., *see* Masood, R., 590
- Martin, J.-M., *see* He, H.-T., 614
- Martin, M. V., *see* Voigt., J. M., 182
- Mason, R. P., *see* Connor, H. D., 443
- Mason, R. P., *see* Maples, K. R., 311
- Mason, S. R., *see* Reilly, P. E. B., 767
- Masood, R., Ahluwalia, G. S., Cooney, D. A., Fridland, A., Marquez, V. E., Driscoll, J. S., Hao, Z., Mitsuya, H., Perno, C.-F., Broder, S., and Johns, D. G. 2'-Fluoro-2',3'-dideoxyarabinosyladenine: A metabolically stable analogue of the antiretroviral agent 2',3'-dideoxyadenosine, 590
- Masood, R., *see* Hao, Z., 157
- Masserano, J. M., *see* Houchi, H., 104
- Massicotte, G., Kessler, M., Lynch, G., and Baudry, M. N-Methyl-D-aspartate and quisqualate/DL- α -amino-3-hydroxy-5-methylisoxazole-4-propionyl c acid receptors: Differential regulation by phospholipase C treatment, 278
- Mathieu, L., *see* Guyda, H. J., 137
- Matlin, S. A., *see* Benz, C. C., 840
- Maurice, D. H., and Haslam, R. J. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic GMP, 671
- Mcdonnell, M., *see* Traber, P. G., 810
- McKeon, A. C., *see* Holland, K. D., 98
- McPhie, P., *see* Berkovich, A., 164
- Meier, G. P., *see* Rettie, A. E., 643
- Meller, E., Goldstein, M., and Bohmaker, K. Receptor reserve for 5-hydroxytryptamine _{1A}-mediated inhibition of serotonin synthesis: Possible relationship to anxiolytic properties of 5-hydroxytryptamine _{1A} agonists, 231
- Meller, E., *see* Enz, A., 560
- Merta, A., *see* De Clercq, E., 658
- Michel, M. C., Regan, J. W., Gerhardt, M. A., Neubig, R. R., Insel, P. A., and Motulsky, H. J. Nonadrenergic [³H]idazoxan binding sites are physically distinct from α_2 -adrenergic receptors, 65
- Michel, M. C., *see* Jasper, J. R., 44
- Mick, S., *see* Rao, T. S., 978
- Mills, D. C. B., Hunchak, K., Karl, D. W., and Kirby, E. P. Effect of platelet activation on the agglutination of platelets by von Willebrand factor, 271
- Minneman, K. P., *see* Han C., 903
- Mirski, S. E. L., *see* Cole, S. P. C., 192
- Mitsuya, Z., *see* Masood, R., 590
- Molinoff, P. B., *see* Ivins, K. J., 622
- Monahan, J. B., Biesterfeldt, J. P., Hood, W. F., Compton, R. P., Cordi, A. A., Vazquez, M. I., Lanthorn, T. H., and Wood, P. L. Differential modulation of the associated glycine recognition site by competitive N-methyl-D-aspartate receptor antagonists, 780
- Mong, S., and Sarau, H. M. Post soluble binding to the leukotriene D₄ receptor from guinea pig lung membranes, 60
- Morel, F., *see* Vandenberghe, Y., 372
- Morris, D., *see* Laurenza, A., 69
- Morrow, A. L., Pace, J. R., Purdy, R. H., and Paul, S. M. Characterization of steroid interactions with γ -aminobutyric acid receptor-gated chloride ion channels: Evidence of multiple steroid recognition sites, 263
- Moscow, J. A., *see* Fairchild, C. R., 801
- Moss, J., *see* Halpern, J. L., 797
- Motulsky, H. J., *see* Michel, M. C., 65
- Müller, U., *see* Reithmann, C., 631
- Murphy, B. J., Rogers, C. A., Sunahara, R. K., Lemaire, S., and Tuana, B. S. Identification, characterization, and photoaffinity labeling of the dihydropyridine receptor associated with the L-type calcium channel from bovine adrenal medulla, 173

N

- Nairn, A. C., *see* Demolle, D., 827
- Nakaki, T., Nakayama, M., Yamamoto, S., and Kato, R. α_1 -Adrenergic stimulation and β_2 -adrenergic inhibition of DNA synthesis in vascular smooth muscle cells, 30
- Nakanishi, S., Yamada, K., Iwahashi, K., Kuroda, K., and Kase, H. KT5926, a potent and selective inhibitor of myosin light chain kinase, 482
- Nakayama, M., *see* Nakaki, T., 30
- Naritoku, D. K., *see* Holland, K. D., 98
- Neubig, R. R., *see* Michel, M. C., 65
- Neumeyer, J. L., *see* Madras, B. K., 833
- Nicoletti, F., Bruno, V., Cavallaro, S., Copani, A., Sortino, M. A., and Canonico, P. L. Specific binding sites for inositolhexakisphosphate in brain and anterior pituitary, 689
- Nishizawa, Y., *see* Choi, O. H., 222

O

- O'Brien, E. E., *see* Fairchild, C. R., 801
- Oesch, F., *see* Dogra, S., 608
- Ogilvie, S., *see* Guyda, H. J., 137
- Ogura, K., Sohtome, T., Sugiyama, A., Okuda, H., Hiratsuka, A., and Watabe, T. Rat liver cytosolic hydroxysteroid sulfotransferase (sulfotransferase a) catalyzing the formation of reactive sulfate esters from carcinogenic polycyclic hydroxymethylarenes, 848
- Okuda, H., *see* Ogura, K., 848
- Olsen, L. D., *see* Cashman, J. R., 319
- Olsen, R. W. *see* Bureau, M., 497

P

- Pace, J. R., *see* Morrow, A. L., 263
- Padgett, W. L., *see* Choi, O. H., 222
- Palayoor, S., *see* Benz, C. C., 840
- Pan, S.-S., and Gonzalez, H. Mitomycin antibiotic reductive potential and related pharmacological activities, 966
- Pan, Y.-P., *see* Kozikowski, A. P., 352
- Paris, H., *see* Langin, D., 876
- Park, S. S., *see* Riddick, D. S., 130
- Paul, A. K., *see* Dhar, A., 519
- Paul, S., Feoktistov, I., Hollister, A. S., Robertson, D., and Biaggioni, I. Adenosine inhibits the rise in intracellular calcium and platelet aggregation produced by thrombin: Evidence that both effects are coupled to adenylate cyclase, 707
- Paul, S. M., *see* Morrow, A. L., 263
- Pemble, S., *see* Vandenberghe, Y., 372
- Perno, C. F., *see* Hao, Z., 157
- Perno, D.-F., *see* Masood, R., 590

- Pessah, I. N., Durie, E. L., Schiedt, M. J. and Zimanyi, I. Anthraquinone-sensitized Ca^{2+} release channel from rat cardiac sarcoplasmic reticulum: Possible receptor-mediated mechanism of doxorubicin cardiomyopathy, 503
- Pfaelzer, C., *see* Madras, B. K., 833
- Picatoste, F., *see* Arbonés, L., 921
- Piguet, P., *see* Hamann, M., 578
- Politi, P. M., Arnold, S. T., Felsted, R. L., and Sinha, B. K. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: Pharmacokinetic and photoaffinity labeling studies, 790
- Prashad, N., Goka, T. J., Barber, R., and Butcher, R. W. cAMP-dependent protein kinase responses of S49 cells are reduced by growth in low epinephrine concentrations, 937
- Presas, M. J., *see* Cashman, J. R., 319
- Prough, R. A., *see* Sherratt, A. J., 198
- Purdy, R. H., *see* Morrow, A. L., 263
- Q**
- Quik, M., Afar, R., Geertsens, S., Audhya, T., Goldstein, G., and Trifaro, J.-M. Thymopoietin, a thymic polypeptide, regulates nicotinic α -bungarotoxin sites in chromaffin cells in culture, 90
- R**
- Ramkumar, V., Barrington, W. W., Jacobson, K. A., and Stiles, G. L. Demonstration of both A_1 and A_2 adenosine receptors in DDT₁ MF-2 smooth muscle cells, 149
- Rampe, D., *see* Schilling, W. P., 80
- Rao, T. S., Cler, J. A., Emmett, M. R., Mick, S., Iyengar, S., and Wood, P. L. BMV-14802 antagonizes harmaline- and D-serine-induced increases in mouse cerebellar cyclic GMP: Neurochemical evidence for a σ receptor-mediated functional modulation of responses mediated by the N-methyl-D-aspartate receptor complex *in vivo*, 978
- Ratansavanh, D., *see* Vandenberghe, Y., 372
- Reasor, M. J., *see* Thomas, D. J., 255
- Regan, J. W., *see* Michel, M. C., 65
- Reilly, P. E. B., Thompson, D. A., Mason, S. R., and Hooper, W. D. Cytochrome P45011A enzymes in rat liver microsomes: Involvement in C₃-hydroxylation of diazepam and nordazepam but not N-dealkylation of diazepam and temazepam, 767
- Reisine, T., *see* He, H.-T., 614
- Reithmann, C., Gierschik, P., Müller, U., Werdan, K., and Jakobs, K. H. *Pseudomonas* exotoxin A prevents β -adrenoceptor-induced upregulation of G_i protein α -subunits and adenylyl cyclase desensitization in rat heart muscle cells, 1, 63
- Relling, M. V., *see* Evans, W. E., 639
- Rens-Domiano, S., *see* He, H.-T., 614
- Rettie, A. E., Bogucki, B. D., Lim, I., and Meier, G. P. stereoselective sulfoxidation of a series of alkyl *p*-tolyl sulfides by microsomal and purified flavin-containing monooxygenases, 643
- Richards, W. G., *see* Gago, F., 341
- Riddick, D. S., Park, S. S., Gelboin, H. V., and Marks, G. S. Effects of 4-alkyl analogues of 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine on hepatic cytochrome P-450 heme, apoproteins, and catalytic activities following *in vivo* administration to rats, 130
- Riek, R. P., *see* Terman, B. I., 526
- Riou, G., *see* B:aaez, A., 377
- Riou, J. F., *see* Báez, A., 377
- Robertson, D., *see* Paul, S., 870
- Roca, D. J., Rozenberg, I., Farrant, M., and Farb, D. H. Chronic agonist exposure induces down-regulation and allosteric uncoupling of the γ -aminobutyric acid/benzodiazepine receptor complex, 37
- Roca, D. J., Schiller, G. D., Friedman, L., Rozenberg, I., Gibbs, T. T., and Farb, D. H. γ -Aminobutyric acid_A receptor regulation in culture: Altered allosteric interactions following prolonged exposure to benzodiazepines, barbiturates, and methylxanthines, 710
- Rogers, C. A., *see* Murphy, B. J., 173
- Rogiers, V., *see* Vandenberghe, Y., 372
- Rorstad, O. P., Wanke, I., Coy, D. H., Fournier, A., and Huang, M. Selectivity for binding of peptide analogs to vascular receptors for vasoactive intestinal peptide, 971
- Rosenwirth, B., *see* De Clercq, E., 658
- Ross, D., *see* Thomas, D. J., 255
- Rozenberg, I., *see* Roca, D. J., 37, 710
- Ryan-Jastrow, T., *see* Gross, R. A., 546
- S**
- Sacaan, A. I., and Johnson, K. M. Characterization of the stimulatory and inhibitory effects of polyamines on [$_3\text{H}$]N-(1-[thienyl]cyclohexyl)piperidine binding to the N-methyl-D-aspartate receptor ionophore complex, 572
- Sadler, A., *see* Thomas, D. J., 255
- Saito, N., *see* Garrett, K. M., 652
- Sakaida, I., Kyle, M. E. and Farber, J. L. Autophagic degradation of protein generates a pool of ferric iron required for the killing of cultured hepatocytes by an oxidative stress, 435
- Sarau, H. M., *see* Mong, S., 60
- Schenkman, J. B., *see* Thummel, K. E., 119
- Schiedt, M. J., *see* Pessah, I. N., 503
- Schiller, G. D., *see* Roca, D. J., 710
- Schilling, W. P., Zaher, M. C., and Rampe, D. Effect of inorganic calcium channel blockers on dihydropyridine binding to cardiac sarcolemma, 80
- Schimerlik, M. I., *see* Tota, M. R., 950, 996
- Schonbrunn, A., *see* Swope, S. L., 758
- Schwabe, U., *see* Wilken, A., 916
- Seamon, K. B., *see* Laurenza, A., 69
- Sebben, M., *see* Bockaert, J., 408
- Seidel, A., *see* Dogra, S., 608
- Seyed-Mozaffari, A., *see* Bidlack, J. M., 50
- Sharma, V. K., *see* Enyeart, J. J., 752
- Sherratt, A. J., Banet, D. E., and Prough, R. A. Glucocorticoid regulation of polycyclic aromatic hydrocarbon induction of cytochrome P4501A1, glutathione S-transferases, and NAD (P)H:quinone oxidoreductase in cultured fetal rat hepatocytes, 198
- Sheu, S.-S., *see* Enyeart, J. J., 752
- Shiverick, T., *see* Guyda, H. A., 137
- Shukla, S. D. *see* Dhar, A., 519
- Shull, J. D., and Gorski, J. Regulation of prolactin gene transcription *in vivo*: Interactions between estrogen, pimoide, and α -ergocryptine, 215
- Siegel, D., *see* Thomas, D. J., 255
- Siegert, P., *see* Dogra, S., 608
- Sigal, I. S., *see* Cheung, A. H., 775
- Sinha, B. K., *see* Politi, P. M., 790
- Sohtome, T., *see* Ogura, K., 848
- Sortino, M. A., *see* Nicoletti, F., 689
- Srivastava, S., *see* Klopman, G., 958
- Stevens, J. L., *see* Hayden, P. J., 468
- Stiles, G. L., *see* Ramkumar, V., 149
- Storm, D. R., *see* Tota, M. R., 950
- Stormann, T. M., Gdula, D. C., Weiner, D. M., and Brann, M. R. Molecular cloning and expression of a dioamine D2 receptor from human retina, 1
- Strader, C. D., *see* Cheung, A. H., 775
- Strader, C. D., *see* Huang, R.-R. C., 304
- Subrahmanyam, V.V., *see* Thomas, D. J., 255
- Sugita, O., *see* Kragh-Hansen, U., 238
- Sugiyama, A., *see* Ogura, K., 848
- Sunahara, R. K., *see* Murphy, B. J., 173
- Surichamorn, W., Forray, C., and El-Fakahany, E. E. Role of intracellular Ca^{2+} mobilization in muscarinic and histamine receptor-mediated activation of guanylate cyclase in N1E-115 neuro-

blastoma cells: Assessment of the arachidonic acid release hypothesis, 860

Swope, S. L., and Schonbrunn, A. Desensitization of islet cells to bombesin involves both receptor down-modulation and inhibition of receptor function, 758

T

Tabakoff, B., *see* Dave, J. R., 367

Tallarida, R. J., *see* Liu-Chen, L.-Y., 243

Tallman, J. F., *see* Garrett, K. M., 652

Tawfik-Schlieper, H., *see* Wilken, A., 916

Taylor, J. B., *see* Vandenbergh, Y., 372

Teller, J. K., *see* Fahien, L. A., 943

Terman, B. I., Riek, R. P., Grodski, A., Hess, H.-J., and Graham, R. M. Identification and structural characterization of α_1 -adrenergic receptor subtypes, 526

Thomas, D. J., Sadler, A., Subrahmanyam, V. V., Siegel, D., Reasor, M. J., Wierda, D., and Ross, D. Bone marrow stromal cell bioactivation and detoxification of the benzene metabolite hydroquinone: Comparison of macrophages and fibroblastoid cells, 255

Thompson, C. L., *see* Andries, M. J., 990

Thompson, D. A., *see* Reilly, P. E. B., 767

Thummel, K. E., and Schenkman, J. B. Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat, 119

Thurman, R. G., *see* Connor, H. D., 443

Tiberi, M., and Magnan, J. Quantitative analysis of multiple κ -opioid receptors by selective and nonselective ligand binding in guinea pig spinal cord: Resolution of high and low affinity states of the κ_2 receptors by a computerized model-fitting technique, 694

Tinelli, S., *see* De Isabella, P., 11

Toews, M. L., *see* Johnson, R. A., 296

Torphy, T. J., and Cieslinski, L. B. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle, 206

Tota, M. R., and Schimerlik, M. I. Partial agonist effects on the interaction between the atrial muscarinic receptor and the inhibitory guanine nucleotide-binding protein in a reconstituted system, 996

Tota, M. R., Xia, Z., Storm, D. R., and Schimerlik, M. I. Reconstitution of muscarinic receptor-mediated inhibition of adenylyl cyclase, 950

Townsend, A. J., *see* Benz, C. C., 840

Traber, P. G., Wang, W., McDonnell, M., and Gumucio, J. J. P450IIB gene expression in rat small intestine: Cloning of intestinal P450IIB1 mRNA using the polymerase chain reaction and transcriptional regulation of induction, 810

Trifaro, J.-M., *see* Quik, M., 90

Tuans, B. S., *see* Murphy, B. J., 173

V

Vanderheyden, P., *see* Hamann, M., 578

Van Lenthe, J. H. *see* Koymans, L., 452

Van Sande, J., Deneubourg, F., Beauwens, R., Braekman, J. C., Doloze, D., and Dumont, J. E. Inhibition of iodide transport in thyroid cells by dysidenin, a marine toxin and some of its analogs, 583

Vasquez, M. I., *see* Monahan, J. B., 780

Vezruguen, A., *see* Balzarini, J., 402

Vezruguen, A., *see* Vandenbergh, Y., 372

Vermeulen, N. P. E., *see* Haenen, G. R. M. M., 412

Vermeulen, N. P. E., *see* Koymans, L., 452

Vitek, P., *see* Garrett, K. M., 652

Vittimberga, F. J., Jr., *see* Madras, B. K., 833

Voigt, J. M., Kawabata, T. T., Burke, J. P., Martin, M. V., Guengerich, F. P., and Baron, J. *In situ* localization and distribution of xenobiotic-activating enzymes and aryl hydrocarbon hydroxylase activity in lungs of untreated rats, 182

Vorum, H., *see* Brodersen, R., 704

W

Wang, G., Dugas, M., Armah, B. I., and Honerjäger, P. Sodium channel modification with full activator reveals veratridine reaction dynamics, 144

Wang, G., Dugas, M., Armah, B. I., and Honerjäger, P. Interaction between DPI 201-106 enantiomers at the cardiac sodium channel, 17

Wang, H.-Y., and Freidman, E. Central 5-hydroxytryptamine receptor-linked protein kinase C translocation: A functional postsynaptic signal transduction system, 75

Wang, S.-L., *see* Guyda, H. J., 137

Wang, W., *see* Traber, P. G., 810

Wanke, I., *see* Rorstad, O. P., 971

Watabe, T., *see* Ishizuka, T., 983

Watabe, T., *see* Ogura, K., 848

Weiner, D. M., *see* Stormann, T. M., 1

Weiner, N., *see* Houchi, H., 104

Werdan, K., *see* Reithmann, C., 631

White, M. M., and Aylwin, M. Niflumic and flufenamic acids are potent reversible blockers of Ca^{2+} -activated Cl-channels in *Xenopus* oocytes, 720

White, M. M., *see* Buller, A. L., 423

Wierda, D., *see* Thomas, D. J., 255

Wiley, J. W. *see* Gross, R. A., 546

Wilken, A., Tawfik-Schlieper, H., Klotz, K.-N., and Schwabe, U. Pharmacological characterization of the adenylyl cyclase-coupled adenosine receptor in isolated guinea pig atrial myocytes, 916

Williams, D. E., *see* Cashman, J. R., 333

Williford, D. J., *see* Enyeart, J. J., 752

Wilson, K. M., *see* Han, C., 903

Wilson, W. E., *see* Lazarus, L. H., 886

Wilson, Y., *see* Hao, Z., 157

Wood, P. L., *see* Monahan, J. B., 780

Wood, P. L., *see* Rao, T. S., 978

Woolkalis, M., *see* He, H.-T., 614

Work, C., *see* Zolnierowicz, S., 554

Wu, F.-S., Gibbs, T. T., and Farb, D. H. Inverse modulation of γ -aminobutyric acid- and glycine-induced currents by progesterone, 597

X

Xia, Z., *see* Tota, M. R., 950

Y

Yamada, K., *see* Nakanishi, S., 482

Yamamoto, S., *see* Nakaki, T., 30

Yasumoto, T., *see* Choi, O. H., 222

Z

Zaher, M. C., *see* Schilling, W. P., 80

Zahniser, N. R., *see* Burnett, D. M., 566

Zhang, K., *see* Hao, Z., 157

Zimanyi, I., *see* Pessah, I. N., 503

Zolnierowicz, S., Work, C., Hutchinson, K., and Fox, I. H. Partial separation of platelet and placental adenosine receptors from adenosine A_2 -like binding protein, 554

Zukin, S. R., *see* Javitt, D. C., 603

Zunino, F., *see* De Isabella, P., 11

A

- Acetylcholine, striatal, dopamine agonist-induced elevation (rat), 560
 Acrolein, inactivation by glutathione transferases, classes alpha, mu, and pi, 251
 Adenosine, inhibition of calcium rise, platelet aggregation, thrombin, 870
 Adenosine monophosphate, cyclic
 accumulation, protein kinase C activators, astrocytoma cells (human), 296
 -dependent protein kinase, growth in low epinephrine concentrations, S49 cells, 937
 generation, agonistic effects, β -adrenergic antagonists, 44
 inhibition of breakdown by cyclic GMP, inhibited platelet function, nitrovasodilators and activators of adenylate cyclase, 671
 Adenylate cyclase
 activators, inhibition of platelet function, nitrovasodilators, 671
 -coupled adenosine receptor, atrial myocytes (guinea pig), 916
 demonstration of A₁ and A₂ adenosine receptors, smooth muscle cells, 149
 5-HT₄ receptors, hippocampal membranes (guinea pig), 408
 inhibition of calcium rise by adenosine, platelet aggregation, thrombin, 870
 regulation by GTP-binding proteins, non-steady state kinetic analysis, 535
 serotonin receptor-mediated activation, neuroblastoma, 742
 Adenylyl cyclase
 muscarinic receptor-mediated inhibition, reconstitution, 950
 prevention of desensitization, *Pseudomonas* exotoxin A, heart muscle cells (rat), 631
 Adrenal gland, angiotensin II receptor binding sites (rat), 347
 Adrenal medulla, L-type calcium channel, dihydropyridine receptor, photoaffinity labeling, 173
 Adrenoceptors
 alpha-1
 inositol phosphate formation, hepatocytes and renal cells, 903
 subtypes, structural characterization, 526
 alpha-2
 idazoxan and methoxy derivative binding, human fat cells, 876
 physical distinction, nonadrenergic idazoxan binding sites, 65
 alpha-1 and beta-2, DNA synthesis, vascular smooth muscle cells (rat), 30
 beta
 agonistic effect, cyclic AMP generation, 44
 sequestration, agonist-promoted activation, 775
 beta-2, *Pseudomonas* exotoxin A, heart muscle cells (rat), 631
 Aging, decreased efficacy of inositol 1,4,5-trisphosphate, calcium mobilization, cerebrocortical microsomes (rat), 566
 Albumin
 human serum
 binding and co-binding of ligands, F-19 NMR, 111
 drug binding, natural mutants, 238
 valproate and palmitate binding, obesity, 704
 Alkyl *p*-tolyl sulfides, stereoselective sulfoxidation, flavin-containing monooxygenases, 643
 Allele, mutant, debrisoquin hydroxylase, family study, 639
 Alprenolol, amplification of cyclic AMP generation, agonistic effects, β -adrenergic antagonists, 44
 Amiloride analogs, phosphorylation of elongation factor-2, vascular endothelial cells (bovine), 827
 Amino acids, single substitution, naturally occurring genetic variant, human thymidylate synthase, 515

- γ -Aminobutyric acid
 benzodiazepine receptor complex, chronic agonist exposure, allosteric uncoupling (chick), 37
 -induced currents, inverse modulation by progesterone (chick), 597
 D-2-Amino-5-phosphonopentanoate, differential modulation, associated glycine recognition site, 780
 D-2-Amino-5-phosphonovalerate, activation by quisqualate, NMDA receptor channels, hippocampal neurons, 477
 Anesthetics, steroid, GABA_A receptors, mechanism of interactions, 429
 Aniline, -induced hemoglobin thiyl free radical formation, 311
 Anthraquinone, -sensitized Ca²⁺ release channel, cardiac sarcoplasmic reticulum (rat), 503
 Antibiotics, mitomycin reductive potential, related pharmacological activities, 966
 Anticonvulsants, cyclopentanones and cyclohexanones (mouse), 98
 Antipsychotics, pimozide, potent Ca²⁺ channel blocker, heart (rat), 752
 Anxiolytic drugs, 5-HT_{1A}-mediated inhibition, serotonin synthesis, receptor reserve (rat), 231
 Arachidonate, maitotoxin effects, calcium channels, PC-12 cells, 222
 Arachidonic acid, muscarinic and histamine receptor-mediated activation, guanylate cyclase, Ca²⁺ mobilization in neuroblastoma cells, 860
 2-Aryl-1,3-dithiolanes, enantioselective *S*-oxygenation, lung enzyme preparations (rabbit), 333
 Aryl hydroxylase, localization and distribution, xenobiotic-activating enzymes, lung (rat), 182
 Assays, mutagenicity, cytochrome P-450IA1 cDNA expression, V79 cells (rat), 608
 Astrocytes, stimulation of glycogen breakdown by histamine, Ca²⁺ permeability (rat), 921
 Astrocytoma, protein kinase C activators, cyclic AMP accumulation (human), 296
 3'-Azido-3'-deoxythymidine, inhibition of DNA synthesis, deoxynucleotide changes, human lymphoid cells, 665

B

- Barbiturates, GABA_A receptor regulation in culture, 710
 Benzamide derivatives, 5-HT₄ receptors, adenylate cyclase, hippocampal membranes (guinea pig), 408
 Benzene, hydroquinone, bioactivation and detoxification, bone marrow stromal cells (mouse), 255
 Benzo(a)pyrene, inhibition of epidermal growth factor binding, receptor autophosphorylation, placental cell culture (human), 137
 Benzodiazepines
 binding site subtypes, discrimination, triakontatetraneuropeptide α -helix, 164
 GABA_A receptor regulation in culture, 710
 Bile, novel type of ornithine-glutathione double conjugate, clebopride (rat), 983
 Biliverdin reductase, variants, bromobenzene-mediated alteration, kidney (rat), 25
 Biotin, fluorescent probes and, dopamine receptors, 833
 BMY-14802, modulation of NMDA receptor-mediated events (mouse), 978
 Bombesin, desensitization of islet cells, receptor down-modulation, inhibition of function, 758
 Bone marrow, stromal cell bioactivation, detoxification, hydroquinone (mouse), 255
 Bradykinin
 B₂ receptors, Balb/c cell mRNA, oocytes (*Xenopus*), 785
 regulation of tyrosine hydroxylase activity, PC-12 cells, 104

Brain

- cerebrocortical microsomes, calcium mobilization, inositol 1,4,5-trisphosphate (rat), 566
- c-fos* mRNA, ethanol withdrawal seizures (mouse), 367
- 5-HT_{1A}-mediated inhibition, serotonin synthesis, receptor reserve (rat), 231
- NMDA receptors, multiple molecules of agonist for activation (rat), 603
- opioid receptors, dermorphin interaction (rat), 886
- solubilization, active somatostatin receptors (rat), 614
- specific binding sites, inositolhexakisphosphate (rat), 689
- sulfhydryl alkylating derivatives, morphine and morphine, μ opioid receptors (rat), 50
- Bromobenzene, -mediated alteration in activity, biliverdin reductase variants, kidney (rat), 25
- α -Bungarotoxin, nicotinic site regulation, thymopoietin, chromaffin cells, 90
- Buspirone, 5-HT_{1A}-mediated inhibition, serotonin synthesis, receptor reserve (rat), 231
- tert*-Butylbicyclopophosphorothionate, electrophysiological study, induced block, spontaneous chloride channels, 578
- tert*-Butyl hydroperoxide, killing of hepatocytes, autophagic degradation of protein, ferric iron pool, 435

C

Calcium

- activated Cl⁻ channels, reversible blockers, niflumic and flufenamic acids (*Xenopus* oocytes), 720
- cytoplasmic, sulfonyleurea-induced oscillations, pancreatic β -cells (mouse), 461
- inhibition of rise by adenosine, platelet aggregation, thrombin, 870
- mobilization
 - activation of guanylate cyclase, neuroblastoma cells, 860
 - inositol 1,4,5-trisphosphate, cerebrocortical microsomes (rat), 566
- permeability, glycogen breakdown stimulated by histamine, astrocytes (rat), 921
- release channel, skeletal muscle sarcoplasmic reticulum, ryanodine as probe, 735
- Calcium channel
 - anthraquinone-sensitized release, cardiac sarcoplasmic reticulum (rat), 503
 - blocker, antipsychotic pimozide, heart (rat), 752
 - inorganic blockers, dihydropyridine binding, cardiac sarcolemma (dog, rat), 80
 - L-type, dihydropyridine receptor, adrenal medulla, 173
 - maitotoxin effects, signal transduction, PC-12 cells, 222
- Calcium current, components in nodose ganglion neurons, regulation, GTP and stable thiol derivatives (rat), 546
- Calmodulin, translocation in neuroblastoma cells, muscarinic receptor, 820
- Carbocyclic 5-iodo-2'-deoxyuridine, carbocyclic (*E*)-5-(2-bromovinyl)-2'-deoxyuridine and, chiral molecules, thymidine kinase of HSV-1 (rabbit), 395
- Carbon tetrachloride, free radical metabolite, reaction with glutathione, 443
- Cardiomyopathy, doxorubicin, anthraquinone-sensitized Ca²⁺ release channel (rat), 503
- CCRF-CEM cells, inhibition of DNA synthesis, 3'-azido-3'-deoxythymidine, deoxynucleotide changes, 665
- Cerebellum, cyclic GMP, BMV-14802, modulation of NMDA receptor-mediated events (mouse), 978
- Cerebral cortex, phosphoinositide metabolism, multiple muscarinic receptor subtypes (rat), 893
- Chemotherapy, antitumor and antimitochondrial properties, gossypol enantiomers, 840

Chloride channels

- Ca²⁺-activated, potent reversible blockers, niflumic and flufenamic acids (*Xenopus* oocytes), 720
- GABA receptor and steroid interactions, 263
- multiple distinct subunits, GABA-A receptor protein, ligand-binding affinities, 497
- spontaneous, electrophysiology, *tert*-butylbicyclopophosphorothionate, 578
- Chloride currents, γ -aminobutyric acid- and glycine-induced, inverse modulation by progesterone (chick), 597
- 5-(2-Chloroethyl)-2'-deoxyuridine, mechanism of action, 658
- Chromaffin cells, regulation of nicotinic α -bungarotoxin sites, thymopoietin, 90
- Cleopride, novel type of ornithine-glutathione double conjugate, excretion in bile (rat), 983
- Computers
 - automated structure evaluation, gastric antiulcer compounds, 958
 - modeling of benzodiazepine receptor binding site, REMOTEDISC, 725
 - simulation, netropsin binding to DNA molecules, 341
- Cyanopindolol, amplification of cyclic AMP generation, agonistic effects, β -adrenergic antagonists, 44
- Cyclic AMP, *see* Adenosine monophosphate, cyclic
- Cyclic AMP phosphodiesterase, rat homologs of *Drosophila dunce* gene code, sensitivity, rolipram and RO 20-1724, 7
- Cyclic GMP, *see* Guanosine monophosphate, cyclic
- Cyclooxygenase, lipoxygenase pathway inhibitors, inositol phosphate formation, pancreatic islets, 928
- Cyclopentanones, convulsant and anticonvulsant, cyclohexanones (mouse), 98
- Cysteine, conjugate toxicity and metabolism, binding to macromolecules, kidney mitochondria (rat), 468
- Cytochrome P-450
 - isozymes, 4-alkyl analogues, 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine (rat), 130
 - multiple forms, immunochemical characterization, nasal microsomes (rabbit), 489
 - reactive metabolites, phenacetin activation, 452
- Cytochrome P-450c, α -naphthoflavone metabolism, liver microsomes (rat), 990
- Cytochrome P450IA1
 - glucocorticoid regulation of induction, polycyclic aromatic hydrocarbon, hepatocytes, 198
 - stable expression of cDNA in V79 Chinese hamster cells, use, mutagenicity testing (rat), 608
- Cytochrome P450IIB, gene expression in small intestine (rat), 810
- Cytochrome P450IIIA, enzymes in liver microsomes, diazepam and nordazepam C₃-hydroxylation (rat), 767

D

- Debrisoquin hydroxylase, identification of mutant allele, family study, 639
- Dermorphin, interaction with brain opioid receptors (rat), 886
- Diabetes, hepatic microsomal P450 expression, testosterone and growth hormone treatment (rat), 119
- Diacylglycerol, phorbol and, molecular geometry, protein kinase C activation, 286
- Diazepam
 - nordazepam and, C₃-hydroxylation, cytochrome P450IIIA enzymes in liver microsomes (rat), 767
 - triakontatetrapeptide, α -helix, benzodiazepine binding site subtypes, 164
 - warfarin and salicylate, binding, serum albumin variants (human), 238
- 2',3'-Dideoxyadenosine, properties of stable analogue, 2'-fluoro-2',3'-dideoxyarabinosyladenosine, 590

- 2',3'-Dideoxyribonucleosides, cytostatic effects, transformed hemopoietic cell lines (human), 328
- 2',3'-Dideoxyuridine-5'-triphosphate, inhibition of HIV reverse transcriptase, DNA chain termination, 157
- 3,5-Diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine, 4-alkyl analogues, P-450 isozymes (rat), 130
- Dihydrolipoate, reaction of ebselen with endogenous thiols, better cofactor than glutathione, 412
- Dihydropyridine, binding to cardiac sarcolemma, effect, inorganic calcium channel blockers (dog, rat), 80
- DNA**
- chain termination activity, inhibition of HIV reverse transcriptase, 2',3'-dideoxyuridine-5'-triphosphate, 157
 - complementary, stable expression of cytochrome P-450IA1, V79 Chinese hamster cells, mutagenicity testing (rat), 608
 - HSV-1-infected, (*E*)-5-(2-iodovinyl)-2'-deoxyuridine, 402
 - inhibition of synthesis
 - adrenergic receptors, vascular smooth muscle (rat), 30
 - 3'-azido-3'-deoxythymidine, human lymphoid cells, 665
 - molecules, netropsin binding, computer simulation, 341
- DNA topoisomerase**
- dependent mechanisms of multidrug resistance, P388 leukemia cells, 11
 - interaction with 3-nitrobenzothiazolo(3,4-*a*)quinolinium, 377
- Dopamine**
- agonist-induced elevation, striatal acetylcholine (rat), 560
 - regulation of prolactin gene transcription, estrogen, pimozone and α -ergocryptine (rat), 215
- Doxorubicin, cardiomyopathy, anthraquinone-sensitized Ca^{2+} release channel (rat), 503
- DPI 201-106, enantiomers, cardiac sodium channel, 17
- Drosophila dunce*, rat homologs of gene code, cyclic AMP phosphodiesterases, rolipram and RO 20-1724, 7
- DT-diaphorase, inhibition by flavonoids, scutellariae radix (rat), 911
- Dysidenin, inhibition of iodide transport, thyroid cells (dog), 583
- E**
- Ebselen, endogenous thiols and, better cofactor than glutathione, peroxidase activity, 412
- Electrophoresis, bromobenzene-mediated alteration, biliverdin reductase variants, kidney (rat), 25
- Electrophysiology, *tert*-butylbicyclophosphorothionate, induced block, spontaneous chloride channels, 578
- Elongation factor-2, induction of phosphorylation by amiloride analogs, vascular endothelial cells (bovine), 827
- Endorphin, sulfhydryl alkylating derivatives, μ opioid receptors, morphine and morphine (rat), 50
- Endothelial cells, vascular, phosphorylation of elongation factor-2, amiloride analogs, 827
- Epidermal growth factor, inhibition of binding by benzo(*a*)pyrene, receptor autophosphorylation, placental cell culture (human), 137
- Epinephrine, low concentrations, cAMP-dependent protein kinase responses, S49 cells, 937
- α -Ergocryptine, regulation of prolactin gene transcription, estrogen, pimozone (rat), 215
- Estrogen**
- enantioselective *S*-oxygenation, *para*-methoxyphenyl-1,3-dithiolane, tissue preparations, 319
 - regulation of prolactin gene transcription, pimozone, α -ergocryptine (rat), 215
- Ethanol, withdrawal seizures, *c-fos* mRNA, brain (mouse), 367
- F**
- Fat cells, human, binding, idazoxan and methoxy derivative, 876
- Fatty acids**
- cyclooxygenase and lipoxygenase pathway inhibitors, modulation, inositol phosphate formation in pancreatic islets, 928
 - valproate and palmitate binding, human serum albumin, obesity, 704
- Fibroblastoid cells, bone marrow stromal cell bioactivation, detoxification, hydroquinone (mouse), 255
- Flavin, -containing monooxygenases, stereoselective sulfoxidation, alkyl *p*-tolyl sulfides, 643
- Flavonoids, inhibition of liver NAD(P)H:quinone acceptor oxidoreductase, scutellariae radix (rat), 911
- Flufenamic acid, reversible blocker of Ca^{2+} -activated Cl^- channels (*Xenopus* oocytes), 720
- Flunitrazepam, allosteric uncoupling, γ -aminobutyric acid/benzodiazepine receptor complex (chick), 37
- 2'-Fluoro-2',3'-dideoxyarabinosyladenine, properties, 590
- 5-Fluoroindole-2-carboxylic acid, activation by quisqualate, NMDA receptor channels, hippocampal neurons, 477
- Fluorophor, fluorescent and biotin probes, dopamine receptors, 833
- Flurbiprofen, detection of site-specific binding and co-binding, ligands, human serum albumin, 111
- Forskolin
- amplification of cyclic AMP generation, agonistic effects, β -adrenergic antagonists, 44
 - irreversible loss of binding sites, α -haloacetyl analogs, platelets (human), 69
- Free radical, formation, hemoglobin thiol, 311
- β -Funaltrexamine, kinetics of binding, μ opioid receptor, 243
- G**
- Genes, encoding for a variant P-glycoprotein, multidrug resistance, glutathione *S*-transferase- π , 801
- Genistein, platelet-activating factor stimulation, tyrosine kinase, phospholipase C relationship (rabbit), 519
- Glucocorticoid, regulation of induction, polycyclic aromatic hydrocarbon, hepatocytes, 198
- Glucose, mimicry of effect by sulfonylurea, cytoplasmic calcium oscillation, pancreatic β -cells (mouse), 461
- Glutathione**
- ebselen and endogenous thiols, peroxidase activity, 412
 - ornithine double conjugate, excretion in bile, clebopride (rat), 983
 - reaction with a free radical metabolite, carbon tetrachloride, 443
 - related enzymes, multidrug resistance, small cell lung cancer, 192
- Glutathione *S*-transferase, subunits 1-2 and 7, mRNA coding changes, hepatocytes (rat), 372
- Glutathione *S*-transferase- π , transfection of genes for P-glycoprotein, 801
- Glutathione transferases, classes alpha, mu, and pi, inactivation of acrolein, 251
- Glutamate dehydrogenase, regulation by Mg^{2+} , magnification of leucine activation, 943
- Glycine**
- differential modulation of recognition site, competitive NMDA receptor antagonists, 780
 - induce currents, inverse modulation by progesterone (chick), 597
- Glycogen, breakdown stimulated by histamine, Ca^{2+} permeability, astrocytes (rat), 921
- Gossypol, enantiomers, antitumor and antimitochondrial properties, 840
- G protein**
- agonist-promoted activation, sequestration, β -adrenergic receptor, 775
 - allosteric antagonists of receptor interactions, 304
 - muscarinic receptor-mediated inhibition, adenylyl cyclase, reconstitution, 950
 - post soluble binding, leukotriene D₄ receptor, lung membranes (guinea pig), 60
- Growth hormone, testosterone and, hepatic microsomal P450 expression, diabetes (rat), 119
- GTP, stable thiol derivatives and, calcium current components, nodose ganglion neurons (rat), 546

GTP-binding proteins

- opioid receptors, spontaneous association, native membranes, 383
- regulation of adenylate cyclase, non-steady state kinetic analysis, 535

Guanine nucleotide-binding protein

- immunological characterization, monoclonal antibody, γ subunit of transducin, 797
- partial agonist effects, atrial muscarinic receptor, reconstituted system, 996

Guanosine monophosphate, cyclic

- cerebellar, BMY-14802, modulation of NMDA receptor-mediated events (mouse), 978
- inhibition of cyclic AMP breakdown, inhibited platelet function, nitrovasodilators and activators of adenylate cyclase, 671

Guanylate cyclase, muscarinic and histamine receptor-mediated activation, intracellular Ca^{2+} mobilization, 860

H

Heart

- cardiac sarcolemma, dihydropyridine binding, calcium channel blockers (dog, rat), 80
- muscle cells, *Pseudomonas* exotoxin A, prevention of β -adrenoceptor-induced up-regulation (rat), 631
- potent Ca^{2+} channel blocker, antipsychotic pimozide (rat), 752
- sodium channel, interaction, DPI 201-106 enantiomers, 17
- sodium channel blockers, size/solubility hypothesis, 855

Hemoglobin, thiyl free radical formation, 311

Hemopoietic cells, transformed, cytostatic effects, 2',3'-dideoxyribonucleosides (human), 328

Hepatocytes

- α_1 -adrenergic receptor subtypes, formation, inositol phosphates, 903
- changes in glutathione S-transferase subunit mRNA expression (rat), 372
- glucocorticoid regulation of induction, polycyclic aromatic hydrocarbon, 198
- killing, autophagic degradation of protein, ferric iron pool, 435

Herpes simplex virus

- inhibition of replication, 5-(2-chloroethyl)-2'-deoxyuridine, mechanism of action, 658

type 1

- (*E*)-5-(2-iodovinyl)-2'-deoxyuridine, DNA incorporation, 402
- thymidine kinase, cybocyclic 5-iodo-2'-deoxyuridine and enantiomers (rabbit), 395

Hippocampus

- 5-HT₄ receptors, adenylate cyclase (guinea pig), 408
- neurons, activation by quisqualate, NMDA receptor channels, 477

Histamine, stimulation of glycogen breakdown, Ca^{2+} permeability, astrocytes (rat), 921

Human immunodeficiency virus, inhibition of reverse transcriptase, DNA chain termination, 2',3'-dideoxyuridine-5'-triphosphate, 157

Hydrocarbon, aromatic, polycyclic, glucocorticoid regulation of induction, hepatocytes, 198

Hydroquinone, bone marrow stromal cell bioactivation, detoxification (mouse), 255

Hydroxymethylarenes, polycyclic, formation of reactive sulfate esters, liver cytosolic hydroxysteroid sulfotransferase (rat), 848

Hydroxysteroid sulfotransferase, cytosolic, formation of reactive sulfate esters, liver (rat), 848

I

Idazoxan

- binding, methoxy derivative, human fat cells, 876
- nonadrenergic binding sites, physical distinction, α_2 -adrenergic receptors, 65

Imidazo[1,2-*a*]pyridines, -pyrazines and, computer-automated structure evaluation, gastric antiulcer compounds, 958

Inositol 1,4,5-trisphosphate, decreased efficacy to elicit calcium mobilization, cerebrocortical microsomes, aged rats, 566

Inositolhexakisphosphate, specific binding sites, brain and anterior pituitary (rat), 689

Inositol phosphate

- formation in hepatocytes and renal cells, α -1 adrenoceptor subtypes, 903
- formation in pancreatic islets, fatty acids, cyclooxygenase and lipoxigenase pathway inhibitors, 928

Intestine, small, P450IIB gene expression (rat), 810

Iodide, inhibition of transport in thyroid cells, dysidenin (dog), 583

(E)-5-(2-Iodovinyl)-2'-deoxyuridine, carbocyclic analogue and, incorporation into HSV-1-infected cell DNA, 402

Ion channels, multiple distinct subunits, GABA-A receptor protein, ligand-binding affinities, 497

Iron, ferric, autophagic degradation of protein, hepatocyte killing, 435

Islet cells, desensitization to bombesin, receptor down-modulation, inhibition of function, 758

K

Kidney

- α_1 -adrenergic receptor subtypes, formation, inositol phosphates, 903
- biliverdin reductase variants, bromobenzene-mediated alteration, electrophoretic pattern (rat), 25
- mitochondria, cysteine conjugate toxicity, binding to macromolecules (rat), 468

KT5926, myosin light chain kinase, 482

L

Leucine, activation, regulation of glutamate dehydrogenase, Mg^{2+} , 943

Ligands

- absence of, receptor coupling, 383
- binding affinities, multiple distinct subunits, GABA_A receptor protein, 497
- nonpeptide, angiotensin II receptor binding sites, adrenal (rat), 347
- selective and nonselective binding, quantitative analysis, multiple κ -opioid receptors in spinal cord (guinea pig), 694
- site-specific binding and co-binding, human serum albumin, F-19 NMR, 111

Lipoxygenase, inhibitors, inositol phosphate formation, pancreatic islets, 928

Liver

- 4-alkyl analogues of 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine (rat), 130
- cytosolic hydroxysteroid sulfotransferase, formation of reactive sulfate esters, carcinogenic polycyclic hydroxymethylarenes (rat), 848
- inhibition of NAD(P)H:quinone acceptor oxidoreductase, flavonoids, *scutellariae radix* (rat), 911

Liver microsomes

- cytochrome P450IIIA enzymes, diazepam and nordazepam C₃-hydroxylation (rat), 767
- α -naphthoflavone metabolism, cytochrome P-450c (rat), 990
- P450 expression, testosterone and growth hormone, diabetes (rat), 119

Lung

- enzyme preparations, enantioselective S-oxygenation, 2-aryl-1,3-dithiolanes (rabbit), 333
- membranes, post soluble binding, leukotriene D₄ receptor (guinea pig), 60
- small cell lung cancer cell line, glutathione-related enzymes, multidrug resistance, 192
- xenobiotic-activating enzymes, localization and distribution, aryl hydroxylase (rat), 182

Lymphoid cells, inhibition of DNA synthesis, 3'-azido-3'-deoxythymidine, deoxynucleotide changes, 665

M

- Macromolecules, cysteine conjugate toxicity, kidney mitochondria (rat), 468
- Macrophages, bone marrow stromal cell bioactivation, detoxification, hydroquinone (mouse), 255
- Magnesium, regulation of glutamate dehydrogenase, magnification of leucine activation, 943
- Maitotoxin, calcium channel effects, signal transduction, PC-12 cells, 222
- para*-Methoxyphenyl-1,3-dithiolane, enantioselective *S*-oxygenation, estradiol effect, tissue preparations, 319
- N*-Methyl-D-aspartate
quisqualate/DL- α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors, phospholipase C treatment (rat), 278
receptors requiring multiple molecules of agonist, activation, brain (rat), 603
- Methylxanthines, GABA_A receptor regulation in culture, 710
- Microsomes
cerebrocortical, inositol 1,4,5-trisphosphate, decreased calcium mobilization (rat), 566
liver, *see* Liver microsomes
nasal, immunochemical characterization, multiple forms of cytochrome P-450 (rabbit), 489
stereoselective sulfoxidation of alkyl *p*-tolyl sulfides, flavin-containing monooxygenases, 643
- Mitochondria
antitumor and antimitochondrial properties, gossypol enantiomers, 840
kidney, cysteine conjugate toxicity, binding to macromolecules (rat), 468
- Mitomycin, antibiotic reductive potential, related pharmacological activities, 966
- Monoamine oxidase-A, binding of Ro 41-1049, 358
- Monoclonal antibodies
immunological characterization, guanine nucleotide-binding protein, γ subunit of transducin, 797
platelet-activating factor stimulation, tyrosine kinase, phospholipase C relationship (rabbit), 519
- Monooxygenases, flavin-containing, stereoselective sulfoxidation, alkyl *p*-tolyl sulfides, 643
- Morphine, morphinone and, sulfhydryl alkylating derivatives, μ opioid receptors (rat), 50
- Mucosa, nasal microsomes, immunochemical characterization, multiple forms of cytochrome P-450 (rabbit), 489
- Multidrug resistance
cells transfected with human genes, variant P-glycoprotein, glutathione *S*-transferase- π , 801
DNA topoisomerase II-dependent mechanisms, P388 leukemia cells, 11
glutathione-related enzymes, small cell lung cancer, 192
tumor cell lines, P-glycoprotein-independent mechanism of resistance, 790
- Muscle, skeletal, sarcoplasmic reticulum calcium release channel, ryanodine as probe, 735
- Muscle, smooth
demonstration, A₁ and A₂ adenosine receptors, 149
tracheal, selective inhibition, cyclic nucleotide phosphodiesterase isozymes (dog), 206
vascular, adrenergic receptors, DNA synthesis (rat), 30
- Mutagenesis, allosteric antagonists, receptor-G protein interactions, 304
- Mutagenicity, stable expression of cytochrome P-450IA1 cDNA, V79 Chinese hamster cells (rat), 608
- Myocytes
atrial, adenylate cyclase-coupled adenosine receptor (guinea pig), 916
inorganic calcium channel blockers, dihydropyridine binding, cardiac sarcolemma (dog, rat), 80

- sodium channel comodification, full activator, veratridine reaction dynamics (rat), 144
- Myosin, light chain kinase, KT5926, 482

N

- NAD(P)H:quinone acceptor oxidoreductase, inhibition by flavonoids, *scutellariae radix* (rat), 911
- NAD(P)H:quinone oxidoreductase, glucocorticoid regulation of induction, polycyclic aromatic hydrocarbon, hepatocytes, 198
- α -Naphthoflavone, metabolism by liver microsomes, cytochrome P-450c (rat), 990
- Netropsin, binding to DNA molecules, computer simulation, 341
- Neuroblastoma
muscarinic and histamine receptor-mediated activation, guanylate cyclase, Ca²⁺ mobilization, 860
muscarinic receptor-mediated translocation, calmodulin, 820
serotonin receptor-mediated activation, adenylate cyclase, 742
- Neurons, nodose ganglion, calcium current components, regulation by GTP and thiol derivatives (rat), 546
- Niflumic acid, reversible blocker of Ca²⁺-activated Cl⁻ channels (*Xenopus* oocytes), 720
- 3-Nitrobenzothiazolo(3,2-*a*)quinolinium, interaction with DNA topoisomerases, 377
- Nitrosobenzene, -induced hemoglobin thyl free radical formation, 311
- Nitrovasodilators, activators of adenylate cyclase and, synergistic inhibition, platelet function, 671
- Nordazepam, diazepam and, C₃-hydroxylation, cytochrome P450III_A enzymes in liver microsomes (rat), 767
- Nuclear magnetic resonance, detection of site-specific binding and co-binding, ligands, human serum albumin, 111

O

- Obesity, valproate and palmitate binding, human serum albumin, 704
- Olfaction, nasal microsomes, immunochemical characterization, multiple forms of cytochrome P-450 (rabbit), 489
- Oocytes
Xenopus
B₂ bradykinin receptor expression, Balb/c cell mRNA, 785
functional acetylcholine receptors, 423
reversible blockers of chloride channels, niflumic and flufenamic acids, 720
- Ornithine, -glutathione double conjugate, excretion in bile, clebopride (rat), 983
- Oxygen
enantioselective *S*-oxygenation
2-aryl-1,3-dithiolanes, lung enzyme preparations (rabbit), 333
para-methoxyphenyl-1,3-dithiolane, estrogen effect, 319
killing of hepatocytes, autophagic degradation of protein, ferric iron pool, 435

P

- Palmitate, valproate binding and, obesity, human serum albumin, 704
- Pancreas
 β -cells, sulfonylurea-induced oscillations, cytoplasmic calcium (mouse), 461
desensitization of islet cells to bombesin, receptor down-modulation, inhibition of function, 758
modulation of inositol phosphate formation, fatty acids, cyclooxygenase and lipoxygenase pathway inhibitors, 928
- PC-12 cells
maitotoxin effects, calcium channels, signal transduction, 222
regulation of tyrosine hydroxylase activity, bradykinin, 104
- Peptide analogs, binding to vascular receptors, vasoactive intestinal peptide, 971
- Peroxidase, activity, ebselen and endogenous thiols, dihydrolipoate, 412

- P-glycoprotein**
 -independent mechanism of resistance to VP-16, multidrug-resistant tumor cell lines, 790
 variant, multidrug resistance in cells, transfection with human genes, 801
- Phenacetin**, mechanisms of activation, reactive metabolites, cytochrome P-450, 452
- Phencyclidine**, binding site of NMDA receptor complex, structural determinants of affinity, 352
- Phenylhydroxylamine**, -induced hemoglobin thyl free radical formation, 311
- Phorbol**, diacylglycerol and, molecular geometry, protein kinase C activation, 286
- Phosphodiesterase isozymes**, cyclic nucleotide, selective inhibition, tracheal smooth muscle (dog), 206
- Phosphoinositide**
 breakdown, maitotoxin effects, PC-12 cells, 222
 hydrolysis, serotonin-2 receptors, clonal cell line, 622
 metabolism in cerebral cortex, multiple muscarinic receptor subtypes (rat), 893
- Phospholipase C**
 glutamate receptors, brain membranes (rat), 278
 platelet-activating factor stimulation, tyrosine kinase, platelets (rabbit), 519
- Photoaffinity labeling**, P-glycoprotein-independent mechanism of resistance, VP-16, multidrug-resistant tumor cell lines, 790
- Pilocarpine**, interaction between atrial muscarinic receptor, inhibitory guanine nucleotide-binding protein, reconstituted system, 996
- Pimozide**
 Ca²⁺ channel blocker in heart (rat), 752
 regulation of prolactin gene transcription, estrogen, α -ergocryptine (rat), 215
- Pituitary**
 anterior, specific binding sites, inositolhexakisphosphate (rat), 689
 regulation of prolactin gene transcription, estrogen, pimozide and α -ergocryptine (rat), 215
- Placenta**
 adenosine receptors, partial separation, adenosine A₂-like binding protein, 554
 inhibition of epidermal growth factor binding, benzo(a)pyrene, receptor autophosphorylation (human), 137
- Platelet-activating factor**, stimulation of tyrosine kinase, phospholipase C, platelets (rabbit), 519
- Platelets**
 aggregation, inhibition of calcium rise, adenosine, 870
 effect of activation on agglutination, von Willebrand factor, 271
 irreversible loss of forskolin binding sites, α -haloacetyl analogs (human), 69
 myosin light chain kinase, KT5926, 482
 placental adenosine receptors and, partial separation, adenosine A₂-like binding protein, 554
 synergistic inhibition of function, nitrovasodilators, activators of adenylate cyclase, 671
- P388 leukemia cells**, multidrug resistance, DNA topoisomerase II mechanisms, 11
- Polyamines**, *N*-(1-[thienyl]cyclohexyl)piperidine binding, NMDA receptor ionophore complex, 572
- Polymerase chain reaction**, P450IIB gene expression, small intestine (rat), 810
- Probes**, fluorescent and biotin, dopamine receptors, 833
- Progesterone**, inverse modulation, γ -aminobutyric acid- and glycine-induced currents (chick), 597
- Prolactin**, regulation of gene transcription, pimozide, estrogen and α -ergocryptine (rat), 215
- Protein**, autophagic degradation, ferric iron pool, hepatocyte killing, 435
- Protein kinase**, cAMP-dependent responses, growth in low epinephrine concentrations, S49 cells, 937
- Protein kinase C**
 activators, cyclic AMP accumulation, astrocytoma cells (human), 296
 myosin light chain kinase, KT5926, 482
 requirements for activation, molecular geometry, phorbol and diacylglycerol, 286
 translocation, central 5-hydroxytryptamine receptor linkage (rat), 75
- Proto-oncogenes**, *c-fos* mRNA, ethanol withdrawal seizures, brain (mouse), 367
- Pseudomonas* exotoxin A**, prevention of β -adrenoceptor-induced up-regulation, G_i protein α -subunits, heart muscle cells (rat), 631
- Pyridine nucleotide cofactors**, biliverdin reductase variants in kidney, bromobenzene-mediated alteration, electrophoretic pattern (rat), 25
- Q**
- Quisqualate**
 activation of NMDA receptor channels, hippocampal neurons, 477
 DL- α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors, NMDA, phospholipase C treatment (rat), 278
- R**
- Receptors**
 acetylcholine, *Xenopus* oocytes, 423
- adenosine**
 adenylate cyclase coupling, atrial myocytes (guinea pig), 916
 platelet and placental, separation from adenosine A₂-like binding protein, 554
- adenosine A₁ and A₂**, smooth muscle cells, 149
- angiotensin II**, binding sites, adrenal (rat), 347
- anthraquinone-sensitized Ca²⁺ release channel**, cardiac sarcoplasmic reticulum (rat), 503
- autophosphorylation**, EGF binding inhibition by benzo(a)pyrene, placental cell culture (human), 137
- B₂ bradykinin**, Balb/c mRNA, oocytes (*Xenopus*), 785
- benzodiazepine**, modeling of binding site, REMOTEDISC, 725
- dihydropyridine**, L-type calcium channel, adrenal medulla, 173
- dopamine D₁ and D₂**, fluorescent and biotin probes, 833
- dopamine D₂**, molecular cloning, human retina (rat), 1
- GABA**, chloride ion channels, steroid interactions, 263
- GABA_A**
 anesthetic steroids, mechanism of interactions, 429
 multiple distinct subunits, ligand-binding affinities, 497
 regulation in culture, 710
- GABA_A subunits**, differential expression, 652
- GABA/benzodiazepine receptor complex**, chronic agonist exposure, allosteric uncoupling (chick), 37
- glutamate**, phospholipase C treatment, brain membranes (rat), 278
- G-protein**, allosteric antagonists, 304
- guanine nucleotide-binding protein**, immunological characterization, 797
- 5-HT₄**, adenylate cyclase, hippocampal membranes (guinea pig), 408
- 5-hydroxytryptamine**, protein kinase C translocation (rat), 75
- leukotriene D₄**, post soluble binding, lung membranes (guinea pig), 60
- M₂ muscarinic agonist-receptor interactions**, sialic acid residues, catalysts, 682
- muscarinic**
 inhibition of adenylate cyclase, reconstitution, 950
 inhibitory guanine nucleotide-binding protein, reconstituted system, 996
 multiple subtypes, phosphoinositide metabolism in cerebral cortex (rat), 893
 translocation of calmodulin, neuroblastoma cells, 820
- muscarinic and histamine**, guanylate cyclase activation, Ca²⁺ mobilization, 860

Receptors—continued

- NMDA**
 activation by quisqualate, hippocampal neurons, 477
 antagonists, modulation of glycine recognition site, 780
 BMY-14802, cerebellar cyclic GMP (mouse), 978
 multiple molecules of agonist for activation, brain (rat), 603
 phencyclidine binding site, structural determinants, 352
 polyamines, *N*-(1-[thienyl]cyclohexyl)piperidine binding, 572
opioid
 dermorphin interaction, brain (rat), 886
 GTP-binding regulatory proteins, spontaneous association, 383
 opioid κ , quantitative analysis, spinal cord (guinea pig), 694
 opioid μ
 kinetics, β -funaltrexamine binding, 243
 sulfhydryl alkylating derivatives, morphine and morphinone (rat), 50
 reserve, 5-HT_{1A}-mediated inhibition, serotonin synthesis (rat), 231
 serotonin, adenylate cyclase activation, neuroblastoma, 742
 serotonin-2, coupled to phosphoinositide hydrolysis, clonal cell line, 622
 somatostatin, solubilization, brain (rat), 614
 striatal acetylcholine, dopamine agonist-induced elevation (rat), 560
 vascular, binding of peptide analogs, vasoactive intestinal peptide, 971
Renal cells, α_1 -adrenergic receptor subtypes, formation, inositol phosphates, 903
Restriction fragments, *Xba*I, mutant allele for debrisoquin hydroxylase, family study, 639
Retina, human, dopamine D2 receptor, molecular cloning (rat), 1
RNA, regulation of prolactin gene transcription, estrogen, pimozone and α -ergocryptine (rat), 215
RNA, messenger
 Balb/c, B₂ bradykinin receptors, oocytes (*Xenopus*), 785
 c-fos, ethanol withdrawal seizures, brain (mouse), 367
 changes in expression of coding, glutathione S-transferase subunits 1-2 and 7, hepatocytes (rat), 372
Ro 20-1724
 rat homologs of *Drosophila dunce* gene code, cyclic AMP phosphodiesterase, 7
 selective inhibition of phosphodiesterase isozymes, tracheal smooth muscle (dog), 206
Ro 41-1049, binding to active site, human monoamine oxidase-A, 358
Rolipram
 rat homologs of *Drosophila dunce* gene code, cyclic AMP phosphodiesterase, 7
 selective inhibition of phosphodiesterase isozymes, tracheal smooth muscle (dog), 206
Ryanodine, probe for functional site, skeletal muscle sarcoplasmic reticulum calcium release channel, 735

S

- Salicylate**, warfarin and diazepam, binding, serum albumin variants (human), 238
Sarcoplasmic reticulum
 calcium release channel, skeletal muscle, ryanodine as probe, 735
 cardiac, anthraquinone-sensitized Ca²⁺ release channel (rat), 503
S49 cells, cAMP-dependent protein kinase responses, growth in low epinephrine concentrations, 937
Scutellariae radix, inhibition of liver NAD(P)H:quinone acceptor oxidoreductase, flavonoids (rat), 911
Seizures, ethanol withdrawal, c-fos mRNA, brain (mouse), 367
Serotonin
 central 5-HT receptor-linked protein kinase C translocation (rat), 75
 5-HT_{1A}-mediated inhibition of synthesis, receptor reserve (rat), 231
 receptors, *see* Receptors

- Sialic acid**, residues, catalysts for M₂-muscarinic agonist-receptor interactions, 682
SK&F 94836, selective inhibition of phosphodiesterase isozymes, tracheal smooth muscle (dog), 206
Sodium channel
 blockers, size/solubility hypothesis, 855
 cardiac, interaction, DPI 201-106 enantiomers, 17
 comodification with full activator, veratridine reaction dynamics (rat), 144
Sodium ions, spontaneous association, opioid receptors, GTP-binding regulatory proteins, 383
Spinal cord, quantitative analysis of multiple κ -opioid receptors, selective and nonselective ligand binding (guinea pig), 694
Steroids
 anesthetic, γ -aminobutyric acid_A receptors, mechanism of interactions, 429
 interactions with GABA receptor-gated chloride ion channels, multiple recognition sites, 263
Striatum, acetylcholine, dopamine agonist-induced elevation (rat), 560
Stromal cells, bioactivation and detoxification, hydroquinone (mouse), 255
Sulfate esters, formation from carcinogenic polycyclic hydroxymethylarenes, liver cytosolic hydroxysteroid sulfotransferase (rat), 848
Sulfhydryl groups, alkylating derivatives of morphine and morphinone, affinity labeling (rat), 50
Sulfonylurea, mimicry of glucose effect, cytoplasmic calcium oscillations, pancreatic β -cells (mouse), 461
Sulindac, detection of site-specific binding and co-binding, ligands, human serum albumin, 111

T

- Temazepam**, diazepam and nordazepam C₃-hydroxylation, cytochrome P450III_A enzymes, liver microsomes (rat), 767
Testosterone, growth hormone treatment and, hepatic microsomal P450 expression, diabetes (rat), 119
N-(1-[Thienyl]cyclohexyl)piperidine, binding to NMDA receptor ionophore complex, stimulatory and inhibitory effects, polyamines, 572
Thiols, ebselen and, better cofactor than glutathione, peroxidase activity, 412
Thrombin, inhibition of calcium rise, platelet aggregation, adenosine, 870
Thymidine kinase, herpes simplex virus type 1, carbocyclic 5-iodo-2'-deoxyuridine, enantiomers (rabbit), 395
Thymidylate synthase, naturally occurring genetic variant, single amino acid substitution, 515
Thymopoietin, regulation of nicotinic α -bungarotoxin sites, chromaffin cells, 90
Thyroid, inhibition of iodide transport, dysidenin (dog), 583
Trachea, smooth muscle, selective inhibition, cyclic nucleotide phosphodiesterase isozymes (dog), 206
Transducin, γ subunit, immunological characterization, guanine nucleotide-binding protein, 797
Triakontatetrapeptide α -helix, discrimination, benzodiazepine binding site subtypes, 164
Tyrosine hydroxylase, regulation of activity by bradykinin, PC-12 cells, 104
Tyrosine kinase, platelet-activating factor stimulation, phospholipase C, platelets (rabbit), 519

U

- Ulcer**, gastric antiulcer compounds, computer-automated structure evaluation, 958

V

- Valproate, palmitate binding and, obesity, human serum albumin, 704
- Vasoactive intestinal peptide, binding of peptide analogs, vascular receptors, 971
- V79 cells, stable expression of cytochrome P-450IA1 cDNA, use in mutagenicity testing (rat), 608
- Veratridine, reaction dynamics, sodium channel comodification, full activator (rat), 144
- von Willebrand factor, agglutination of platelets, effect, platelet activation, 271
- VP-16, P-glycoprotein-independent mechanism of resistance, multi-drug-resistant tumor cell lines, 790

W

- Warfarin, salicylate and diazepam, binding, serum albumin variants (human), 238

X

- Xenobiotic-activating enzymes, localization and distribution, aryl hydroxylase activity, lung (rat), 182

Z

- Zaprinast, selective inhibition of phosphodiesterase isozymes, tracheal smooth muscle (dog), 206

**Copyright © 1990 by the American Society for
Pharmacology and Experimental Therapeutics**

INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: identification and characterization of receptors for hormones, growth factors, neurotransmitters, toxins, and other drugs; analysis of receptor response pathways; drug effects on metabolic pathways, biosynthesis and degradation of macromolecules, and cellular regulatory mechanisms; analysis of drug-receptor and drug-enzyme interactions; effects of drugs on structure and properties of macromolecules and membranes; relationships between drug structure and activity; molecular mechanisms of drug metabolism; distribution and transport between biological compartments; molecular mechanisms of chemical mutagenesis, carcinogenesis, and teratogenesis; and molecular mechanisms of selective toxicity, drug allergy, and pharmacogenetics.

Page charges. Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to **Dr. William A. Catterall, Editor, *Molecular Pharmacology*, Department of Pharmacology, SJ-30, University of Washington, Seattle, Washington 98195, U. S. A.**

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. *Therefore, all manuscripts must be accompanied either by a check for \$30 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution.* The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, $8\frac{1}{2} \times 11$ inches (ca. 215×280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made.

Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. If the submitted manuscript utilizes or makes bibliographic reference to articles in press, copies should be included with the manuscript. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Accelerated Communications. In order to provide a mechanism for rapid publication of novel experimental findings of unusual and timely significance, manuscripts will be accepted for consideration as Accelerated Communications. Accelerated Communications are not intended for publication of preliminary results. Manuscripts submitted under this category should present novel results that are clearly documented and should make a conceptual advance in their field. They will be reviewed by the same criteria applied to regular papers in *Molecular Pharmacology*. The manuscript should be accompanied by a transmittal letter briefly outlining the significance of the work and providing a list of at least three scientists who would be appropriate reviewers.

Accelerated Communications will be reviewed as rapidly as possible with the aim of reaching an editorial decision within four weeks of receipt of the manuscript. It is expected that Accelerated Communications which are accepted will be published in essentially the form submitted. Manuscripts accepted without revision will be published within four to five months of initial receipt. Manuscripts accepted with a requirement for minor revisions will be published two or three months following receipt of a suitably revised version.

All manuscripts that require major revisions or that do not fit the criteria for Accelerated Communications will be returned to authors for revision and further consideration as a regular paper. Such manuscripts will retain the original submission date if revised versions are received in a timely manner.

Accelerated Communications may be submitted in the same style as regular manuscripts. Results and Discussion may be combined at the discretion of the authors. Manuscripts must not exceed five printed pages in the journal. This corresponds approximately to 25 double-spaced typewritten pages (1-inch margins) including all components of the manuscript and counting each figure as a page of typewritten text. Manuscripts that are judged to be too long will be considered as regular papers.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 261, pp. 1-11, January 10, 1986). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text,

including title and complete pagination. Examples: 1. Goren, J. H., L. G. Baue, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Chernow, B., and J. T. O'Brian. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (M. G. Ziegler and C. R. Lake, eds.). Williams and Wilkins, Baltimore, 439-449 (1984). 3. Snedecor, G. W., and W. G. Cochran. *Statistical Methods*. Iowa State University Press, Ames (1967). (7) Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers after such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used (\times , \circ , \bullet , \square , \blacksquare , \triangle , \blacktriangle , \odot). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Page proof. Authors will be billed for substantial changes in page proof. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.

Newsworthy and timely
articles in your field


MOLECULAR PHARMACOLOGY

Editor: **William A. Catterall, PhD**, University of Washington, Seattle, Washington

Is your special interest receptors and neurotransmitters... drug metabolism... antibiotic and anticancer drug actions... or other areas related to the molecular basis of drug action? If so, you should be subscribing to **MOLECULAR PHARMACOLOGY**.

The editor's and editorial board's high standards ensure that the papers you read in **MOLECULAR PHARMACOLOGY** are on the cutting edge of research on drug action and selective toxicity at the molecular level. Original applications of biochemistry, biophysics, genetics, and molecular biology are juxtaposed with innovative pharmacologic research to elucidate basic problems in pharmacology and toxicology, including such areas as molecular mechanisms involved in drug receptor-effector coupling, xenobiotic metabolism, and antibiotic and anticancer drug action. Start your subscription today to ensure access to the most newsworthy papers in your field. **Monthly**

Call toll-free to start your subscription immediately, **1-800-638-6423** from anywhere in the U.S. (In Maryland call **1-800-638-4007**).



YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscription today!

Molecular Pharmacology (monthly)

☐ Individual: \$85/yr ☐ Institutions: \$185/yr

(Please add \$25.00 outside the U.S.)

☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

name _____

address _____

city state zip _____

Payment options:

☐ Check enclosed ☐ VISA

☐ Bill me

☐ MasterCard

☐ American Express

card # _____

signature/P.O.# _____

MD residents, please add 5% sales tax. Subscriptions from outside the US and Canada must be prepaid, *in US dollars only*. Rates valid for orders received before October 31, 1990.

Please allow 10 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request.

Williams & Wilkins

MOL 52003

P.O. Box 23291
Baltimore, Maryland 21203-9990

Broadway House
2-6 Fulham Broadway
London SW6 1AA England


J0006S01



Need shelf space?

Williams & Wilkins is your source for back issues of this journal in microform.

Free Up 98% Of
Your Shelf Space With
Microform Conversion



MICROFILM editions are available for this journal direct from the publisher. Many Williams & Wilkins journals as well as those journals distributed by the Publishing Services Division of Waverly, Inc., are also available for a single volume year or on a standing order basis.

For ordering information: Write to the address below or call **TOLL FREE 1-800-638-6423**. In Maryland call **1-800-638-4007**.

☐ **Please send me microform back issue ordering information for**

Journal Name _____

Name _____

Title _____

Address _____

City/State/Zip _____

Mail to:

Williams & Wilkins
Microform Sales
Attention: Yvonne Hahn
428 East Preston Street
Baltimore, MD 21202

or

The Broadway Centre
2-6 Fulham Broadway
London SW6 1AA England

Formats available:

- 16-mm reel
- 35-mm reel
- 16-mm cartridge (3M or Kodak)
- positive or negative film

Previous Editors

- 1965** Avram Goldstein, *Editor*. Stanford University.
1968 Paul Talalay, *Editor*; Donald S. Coffey, *Associate Editor*. Johns Hopkins University.
1971 Steven E. Mayer, *Editor*, Palmer W. Taylor, *Associate Editor*. University of California at San Diego.
1975 George I. Drummond, *Editor*; H. Joseph Goren, *Associate Editor*. University of Calgary.
1978 Norman Kirschner, *Editor*; Theodore A. Slotkin, *Associate Editor*. Duke University.
1983 Joel G. Hardman, *Editor*; Lee Limbird, F. Peter Guengerich, *Associate Editors*. Vanderbilt University.

INFORMATION TO SUBSCRIBERS

MOLECULAR PHARMACOLOGY is published monthly, two volumes a year, beginning in January & July. Instructions to Authors will be found in every issue.

Correspondence concerning business matters should be addressed to Williams & Wilkins, 428 East Preston St., Baltimore, Maryland 21202-3993 U.S.A.

Correspondence regarding editorial matters should be addressed to the Editor, Dr. William A. Catterall, Department of Pharmacology, SJ-30, University of Washington, Seattle, WA 98195.

Annual Subscription Rates—U. S. A. AND POSSESSIONS: personal, \$85.00; institutional, \$185.00, single copy, \$17.00. FOREIGN: personal, \$110.00; institutional, \$210.00; single copy, \$20.00. JAPAN: personal, \$151.00; institutional, \$251.00 (includes air freight). (Prices subject to change.) Institutional (multiple reader) rate applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial, and private institutions and organizations. Foreign subscribers who wish to have issues sent by air mail may inquire of the publisher for the additional cost.

Japanese Yen price is available from our sole agent: USACO Corporation, 13-12 Shimbashi 1-Chome, Minato-Ku, Tokyo 105, Japan, telephone 03-502-6471.

Change of address: Publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicates can be obtained (if available) from the publisher at the regular price of single issues.

New subscriptions and renewals are entered to begin with the January or July issue.

To avoid a break in your series, subscriptions should be renewed promptly. The publisher cannot guarantee to supply back issues on belated renewals.

Reprints of individual articles are available *only* from authors.

Microfilm. For availability, inquire of Williams & Wilkins.

Williams & Wilkins, Baltimore, MD. 21202-3993 U. S. A.